Lab Ultrafiltration and Purification Products Catalog

Lab Ultrafiltration
and Purification
Products
Table of Contents
General Information
Ultrafiltration Applications 4
Lab Ultrafiltration Devices 5
Ultrafiltration Process Methods 5
Membrane Performance Characteristics 6
Membrane Selection Guide 7
---
Protein and Macromolecule Concentration 9
Centrifugal and Pressurized Ultrafiltration
---
Vivaspin® 500 10
Vivaspin® 2 12
Vivaspin® Filtrate 14
---
Vivaspin® Turbo 4 PES 16
Vivaspin® 6 18
Vivaspin® 15R 20
---
Vivaspin® Endotest 22
Vivaspin® Turbo 15 RC 26
Vivaspin® 20 28
Vivaspin® 100 30
---
Vivaspin® Equipment and Accessories 32
Tangential Flow Filtration
-
Vivaflow® 50 34
Vivaflow® 50R 36
Vivaflow® 200 38
Vivaflow® Equipment and Accessories 40
Ultrafiltration Membrane Discs 42
2
DNA Concentration 45
Vivacon® 500 46
Vivacon® 2 49
Protein Purification 53
Vivaclear Centrifugal Filters 54
Vivapure® Ion Exchange Purification Products 56
Virus Purification and Concentration 59
---
Vivapure® Virus Purification and Concentration Kits 60
Adenovirus Purification 61
Vivapure® Adenopack 20 62
---
5Vivapure® Adenopack 500 65
Lentivirus Purification 66
Vivapure® Lentiselect 40 67
Application Notes 71
1. Desalting and Buffer Exchange with Vivaspin® Centrifugal
Concentrators 72
2. Treatment of Vivaspin® Concentrators for Improved Recovery
of Low-Concentrated Protein Samples 75
3. Scouting Protein Purification Conditions Using Vivapure® Centrifugal
Ion Exchange Membrane Absorbers 78
4. Concentration and Purification of Viruses by using Ultrafiltration,
Incl. Coronavirus - a Short Review 83
5. Sartorius Ultrafiltration Products in the Preparation of Biological
Nanoparticles and Medical Nanocarriers 95
6. Vivaflow® and Vivaspin® Workflow in Protein Research Laboratories 101
3
Ultrafiltration Applications
Ultrafiltration is a convective process Solute Concentration

using anisotropic semi-permeable Ultrafiltration membranes are used
membranes to separate to increase the solute concentration
macromolecular species and solvents of a desired biological or inorganic
– primarily on the basis of size. It is species. Macromolecules are retained
particularly appropriate for the by the membrane when they are sig-
concentration of macromolecules nificantly larger than the nominal pore
and can also be used for purification size, while salts and microsolutes are
or solvent exchange. Ultrafiltration is removed with the solvent.
Solute concentration a gentle, non-denaturing method
that is more efficient and flexible Solute Fractionation
-
than alternative processes. Ultrafiltration is a cost effective
method for separating samples into
Typical Applications size-graded components providing
Concentration | desalting of proteins, that the desired fractions have at
--
enzymes, DNA, monoclonal antibod- least a 10-fold difference in molecular
ies, immunoglobulins, extracellular weight. During filtration, the
vesicles, viruses and nanoparticles permeating solute remains at its initial
Forensic DNA sample concentration concentration whilst the retained
--
prior to sequencing reaction macromolecules will be enriched.
Solute fractionation Peptide fractionation in FASP
(filter-aided sample preparation) Solute Desalting or Purification
--
Free drug | hormone assays A solution may be purified from salts,
Removal of primers from PCR solvents and low molecular weight
amplified DNA materials by diafiltration. Multiple
--
Removal of labeled amino acids solvent exchanges will progressively
and nucleotides purify macromolecules from
HPLC sample preparation contaminating microsolutes, which are
--
Deproteinization of samples typically removed most efficiently by
Recovery of biomolecules from cell adding solvent to the sample at a rate
culture supernatants | lysates equal to the speed of filtration. This is
-
Solute desalting or purification Mammalian cell harvesting called continuous diafiltration, and it
Cell washing, virus purification, cell replaces time-intensive techniques
debris removal and depyrogenation such as dialysis.
Environmental sample clarification |
concentration
4 General Information
Lab Ultrafiltration Devices
Sartorius develops devices dedicated support tools to help users select the
to optimizing laboratory ultrafiltration optimum device and process for their
processes with minimal time sample type.
requirements while maximizing
Vivaspin® Turbo
1.5
recovery, reliability and robustness. Visit www.sartorius.com for more

1.0
0.5
technical and application support

In addition Sartorius are continually material.
building technical and application
Centrifugal
Ultrafiltration Process Methods
Sartorius offers a comprehensive Pressure-Fugation

choice of operating methods for (5 to 15 mL starting volumes)
ultrafiltration and diafiltration. The A unique Sartorius method that
guidance below will support you in combines gas pressure with
selecting the most suitable method, centrifugation, with process times
Pressure and pressure-fugation depending on sample volume, typically 30 to 50% faster than
equipment available, and the desired centrifugation alone. Vivaspin® 20 can
filtration speed and process control. be operated this way.
Centrifugal Crossflow | TFF

(0.1 to 90 mL starting volumes) (0.1 to 5 L starting volumes)
Driven by centrifugal force, solvent and The solution to be processed is pumped
microsolutes are cleared through the under pressure across an ultrafiltration
ultrafiltration membrane and into a membrane and then returned to the
filtrate container, usually positioned original reservoir. The solution is
below. This gentle process is quick to progressively concentrated or purified
Crossflow | TFF set up and offers fast filtration speeds as solvent and microsolutes pass
with most solutions. Twelve centrifugal through the membrane into a separate
devices are offered from the Vivaspin® filtrate vessel. Vivaflow® cassettes are
and Vivacon® families. offered for this method.
Pressure
(5 to 98 mL starting volumes)
Pressurized air or an inert gas provide
the vector for ultrafiltration. For
increased process speed, pressurized
devices can be placed on an orbital
shaker, where agitation impedes
macromolecules from polarizing on
the membrane surface. Vivaspin® 20
and 100 can be operated using gas
pressure.
General Information 5
Membrane Performance Characteristics
Sartorius offers an extended range of This is a hydrophillic membrane

membranes to cover the majority of suitable for general samples, with
ultrafiltration requirements. The ultra-low protein adsorption and high
following is a guide to selecting the chemical compatibility.
most appropriate membranes Regenerated cellulose is especially
according to their typical well suited to ultrafiltration of
performance characteristics. oligonucleotides and peptides.
However, membrane behavior and
performance can be highly Hydrosart® (HY)
dependent on the specific Demonstrating the same properties as
characteristics of each sample. regenerated cellulose, but with the
Therefore, it is recommended to added benefit of enhanced
experiment with multiple membrane performance characteristics and
materials when optimizing your extremely low protein binding.
ultrafiltration process. Hydrosart® is another membrane of
choice for applications such as
Polyethersulfone (PES) concentration and desalting of
This is a low binding membrane that immunoglobulin fractions.
provides excellent performance with
most solutions and exceptional Cellulose Triacetate (CTA)
recovery of negatively charged target High hydrophilicity and very low non-
molecules. Polyethersulfone specific binding characterize this
membranes are usually preferred for membrane. Cast without any support
their low fouling characteristics, that could trap or bind passing
exceptional flux and broad pH microsolutes, these membranes are
compatibility. preferred for sample cleaning and
protein removal, and when high
Regenerated Cellulose (RC) recoveries from the filtrate solution is
The Sartorius regenerated cellulose of primary importance.
membrane has been uniquely
developed to ensure optimal
performance in the lab ultrafiltration
devices.
Membrane Performance Comparisons
Membrane Frequently preferred for:
Polyethersulfone & Regenerated Cellulose Concentration

3 kDa MWCO Desalting
5 kDa MWCO Buffer exchange
10 kDa MWCO Fractionation
30 kDa MWCO
50 kDa MWCO
100 kDa MWCO
Cellulose triacetate Deproteinization

5 kDa MWCO Free|bound drug studies
10 kDa MWCO Whenever the filtrate is being analyzed
20 kDa MWCO
Hydrosart® Concentration
2 kDa MWCO Desalting
5 kDa MWCO Buffer exchange
10 kDa MWCO Fractionation
30 kDa MWCO Membrane evaluation for scale up
6 General Information
Membrane Selection Guide
The advanced designs and low surface of the sample container. Whilst
adsorption materials that characterize the relative adsorption will be
Sartorius ultrafilters, offer a unique proportionately less important than on
combination of faster processing the membrane, due to the higher total
speeds and highest target molecule surface area, this can be the major
recoveries. Providing that the source of yield loss.
appropriate sample capacity,
membrane material and MWCO are Process Optimization
selected, these devices will typically When the highest recoveries are
yield recoveries in excess of 90% when crucial, particularly when working with
--
the initial sample contains > 0.1 mg/mL solute quantities in the microgram
of the solute of interest. The majority of range, Sartorius recommends that
any loss occurs through non-specific users consider the following:
binding to the membrane surface and | Select the smallest device that suits
or the sample container polymer. the sample volume.
--
Take advantage of the extra speed
Adsorption to the Membrane of Sartorius products by refilling a
Depending on sample characteristics smaller device repeatedly.
relative to the membrane type used, Select the lowest MWCO membrane
solute adsorption on the membrane that suits the application.
-
surface is typically 2-10 μg/cm2. This can Reduce pressure or centrifugal
increase to 20-100 μg/cm2 when the force to approximately half of the
filtrate is of interest and the solute must recommended maximum.
pass through the whole internal Avoid over-concentration. The
-
structure of the membrane. Typically a smaller the final concentrate volume,
higher cut-off membrane will bind the more difficult it is to achieve
more than a low molecular weight complete recovery.
-
alternative. If feasible, after sample retrieval,
rinse the device with one or more
Adsorption to the Sample Container drops of buffer.
Although every effort is made to Pretreat the device overnight with a
minimize this phenomenon by the passivation solution such as 5% SDS,
selection of low binding materials and Tween 20 or Triton X-100, then rinse
tool production to optical standards, thoroughly before use.
some solute will bind to the internal
Membrane Selection Guide (Recommended MWCO)

Application < 5 kDa 10 kDa 30 kDa 50 kDa 100 kDa > 300 kDa
Bacteria
Enzymes
Extracellular vesicles
Growth factors
IgG and mAbs
Nucleic acids
Oligonucleotides
Peptides
Viruses
Yeast
For highest recovery, select a membrane MWCO which is a maximum of one third to half the
molecular weight of the solute to be retained
General Information 7
8 Chapter Site Title
Protein and Macromolecule
Concentration
Table of Contents
Vivaspin® 500 10
Vivaspin® 2 12
Vivaspin® Filtrate 14
Vivaspin® 6 18
Vivaspin® 15R 20
Vivaspin® Endotest 22
Vivaspin® Turbo 15 RC 26
Vivaspin® 20 28
Vivaspin® 100 30
Vivaspin® Equipment and Accessories 32
Vivaflow® 50 34
Vivaflow® 50R 36
Vivaflow® 200 38
Vivaflow® Equipment and Accessories 40
Ultrafiltration Membrane Discs 42
9
Vivaspin® 500
100 to 500 μL samples The legacy patented vertical

Vivaspin® 500 centrifugal filter units membrane design and thin channel
offer a simple, one step procedure for filtration chamber (US 5,647,990),
sample preparation. They can minimize membrane fouling and
effectively be used in fixed angle provide fast concentrations – even
rotors a
ccepting 2.2 mL centrifuge with particle-loaded s olutions.
tubes.
Technical Specifications
Concentrator capacity
Swing bucket rotor do not use
Fixed angle rotor 500 µL
Dimensions
100
50 75
Length x diameter 50 x 11 mm
50
Active membrane area 0.5 cm²
Hold-up volume, membrane and support < 5 µL

100
75
50
Dead-stop volume 5 µL
Materials of construction
11 Body Polycarbonate (PC)
Filtrate vessel Polypropylene (PP)
Concentrator cap Polycarbonate (PC)
Membrane Polyethersulfone (PES)
Equipment Required
Centrifuge
Rotor type Fixed angle (min. 40°)
Rotor cavity To fit 2.2 mL (11 mm) conical bottom tubes
Maximum RCF 12,000 g
Concentrate recovery
Pipette type Fixed or variable volume
Recommended tip Thin gel loader type
10 Protein Concentration Centrifugal Filtration Vivaspin® 500

Typical Performance Characteristics
Time to concentrate up to 30x

at 20°C and solute recovery
Rotor Fixed angle
Centrifugal force 12,000 g
Start volume 500 µL
Time Recovery
Aprotinin 0.25 mg/mL (6.5 kDa)

3 kDa MWCO PES 30 min 96%
BSA 1.0 mg/mL (66 kDa)

IgG 0.25 mg/mL (160 kDa)

Ordering Information
Vivaspin® 500 PES 25 pc 100 pc
3 kDa MWCO VS0191 VS0192
1,000 kDa MWCO VS0161 VS0162
0.2 µm VS0171 VS0172
Protein Concentration Centrifugal Filtration Vivaspin® 500 11

Vivaspin® 2
0.4 to 3 mL samples Also unique to Vivaspin® 2 is the

Vivaspin® 2 bridges the gap between choice of directly pipetting the
the 500 μL and 4 mL centrifugal concentrate from the dead-stop
concentrators. This device combines pocket built into the bottom of the
the speed of the classic Vivaspin® concentrator, or alternatively reverse
products with low internal surface and spinning into the concentrator
membrane areas for superior recovery cap. Both methods result in
recoveries from very dilute solutions. near total concentrate recoveries.
Available with a choice of

polyethersulfone, Hydrosart® or
cellulose triacetate membranes,
Vivaspin® 2 offers the highest flexibility
for process optimization.
2.0
mL
1.5
1.5
1.0
100K
1.0
MWCO
126
200
µL
100
20 Swing bucket rotor 3 mL
Fixed angle rotor 2 mL
Dimensions
Active membrane area 1.2 cm2

17
Hold-up volume, membrane < 10 μL
Dead-stop volume 8 μL
Body Polycarbonate (PC)
Filtrate vessel Polycarbonate (PC)
Concentrator cap Polycarbonate (PC)

Hydrosart® (HY)
Cellulose Triacetate (CTA)
Equipment Required
Centrifuge
Rotor type Swing bucket Fixed angle (min. 25°)
Rotor cavity To fit 15 mL (17 mm) To fit 15 mL (17 mm)

conical bottom tubes conical bottom tubes
Maximum RCF 4,000 g 8,000 g
Pipette type Fixed or variable volume Fixed or variable volume
Recommended tip Thin gel loader type Thin gel loader type

2.0
mL
1.5
Time to concentrate up to 30×
1.5
1.0
100K
1.0
MWCO
Rotor Fixed angle

Integral deadstop 200
µL
100
avoids risk of 20

concentrating
Start volume 2 mL
to dryness
Time Recovery
PES, HY or CTA membranes Insulin chain A 0.1 mg/mL (2.5 kDa)

2 kDa MWCO HY 35 min 95%
Aprotinin 0.25 mg/mL (6.5 kDa)

20
100
µL
200
MWCO
1.0
100K
1.0
1.5
10 kDa MWCO CTA 10 min 96%

1.5
mL
2.0


Reverse spin concentrate retrieval 30 kDa MWCO PES 10 min 96%
1,000 kDa MWCO VS0261 VS0262
0.2 μm VS0271 VS0272
Vivaspin 2 CTA
®
10 kDa MWCO VS02V1 VS02V2
20 kDa MWCO VS02X1 VS02X2
Vivaspin 2 HY
®
2 kDa MWCO VS02H91 VS02H92

Vivaspin® Filtrate
0.5–2.5 mL samples The ultrafiltrate is collected in the

Vivaspin Filtratre® is a ready-to-use floating filtrate tube, where it is readily
unit for low volume centrifugal accessible without disassembly.
---
ultrafiltration to separate proteins from
low molecular weight substances in Vivaspin® Filtrate is ideal for the
biological samples. following applications:
--
Drug binding studies
Vivaspin Filtratre® features a unique Isolation of metabolites from serum
design that enables ultrafiltration in Protein removal from blood samples
the direction opposite to centrifugal Cleaning of liposomes
force. This is so effective in preventing Virus removal
premature blockage of the filter that
even whole blood samples can be
deproteinized.
Swing bucket rotor 2.5 mL
93
Fixed angle rotor 2.5 mL
Dimensions
max. 2.5 mL
14
Centrifuge tube Polystyrene (PS)
Filtrate tube Styrene Acrylonitrile (SAN)
Concentrator cap Polyethylene (PE)
Membrane Cellulose Triacetate (CTA)
Polyethersulfone (PES)
Equipment Required
Centrifuge

conical | flat bottom tubes conical | flat bottom tubes
14 Protein Concentration Centrifugal Filtration Vivaspin® Filtrate

Easy-to-use Typical Performance Characteristics
Time to filter Time to filter Passage of

50% of sample 90% of sample sample species
volume volume volume
Start volume 2.5 mL

5 kDa MWCO 300 min – 0%
10 kDa MWCO 35 min 80 min 2%
Remove filtrate tube, pour in sample Blue Dextran 0.1 mg/mL (2,000 kDa)
Vivaspin® Filtrate CTA 12 pc
5 kDa MWCO 13229-E
10 kDa MWCO 13239-E
20 kDa MWCO 13249-E
Replace filtrate tube Vivaspin Filtrate PES

®
300 kDa MWCO 13279-E
References R. H. Christenson, S. D. Studenberg,

P. Nebinger and Koel (1993). S. Beck-Davis and F. A. Sedor (1987).
Determination of acyclovir by Digoxin-like immunoreactivity
Centrifuge ultrafiltration and high-performance eliminated from serum by centrifugal
liquid chromatography. ultrafiltration before fluorescence
J. Chromatography 619, 342-344 polarization immunoassay of digoxin.
Clinical Chemistry 33, 606-608
F. da Fonseca-Wollheim, K.-G. Heinze,
K. Lomsky and H. Schreiner (1988).
Serum ultrafiltration for the elimination
of endogenous interfering substances
in creatinine determination.
J. Clin. Chem. Clin. Biochem. 26,
523-525
Recover …or use forceps
the filtrate… to remove the
filtrate tube
and access the
concentrate
Protein Concentration Centrifugal Filtration Vivaspin® Filtrate 15

Vivaspin® Turbo 4 PES
2 to 4 mL samples The optimized design and sleek

Vivaspin® Turbo 4 PES offers the internal profile ensure maximum
fastest sample concentration with the process speeds all the way down to the
highest recoveries. This device can last few microliters, resulting in more
handle up to 4 mL sample volumes in than 100-fold concentration.
swing bucket and fixed angle rotors
that accept 15 mL conical bottom UV joining technology provides a
centrifuge tubes. smooth transition between membrane
and housing, allowing collection of the
entire concentrated sample from the
unique, pipette tip-friendly angular
dead-stop pocket.
122
Swing bucket rotor 4 mL
Dimensions
Length x diameter 122.5 x 17 mm
17 Dead-stop volume, swing bucket 40 μL
Dead-stop volume, fixed angle 30 μL
Body Styrene Butadiene Copolymer (SBC)
Concentrator cap Polypropylene (PP)
Equipment Required
Centrifuge

Maximum RCF, 100 kDa MWCO 3,000 g 5,000 g
16 Protein Concentration Centrifugal Filtration Vivaspin® Turbo 4

Visit us at Typical Performance Characteristics
www.sartorius.com/
VivaspinTurbo4 Time to concentrate up to 30×
for further information. at 20°C and solute recovery
--
Here you can find instruc- Rotor Swing bucket Fixed angle (25°)
tions on how to use Vivaspin® Centrifugal force* 4,000 g 7,500 g
Turbo 4 PES for:
Start volume 4 mL 4 mL
Desalting and buffer
Time Recovery Time Recovery
exchange
--
Preparation of biological Cytochrome c (12.4 kDa)
nanoparticles and medical 3 kDa MWCO PES 60 min 98% 80 min 96%
5 kDa MWCO PES 40 min 95% 50 min 94%
nanocarriers
Concentration and Lysozyme (14.3 kDa)
-
purification of viruses 5 kDa MWCO PES 50 min 94% 60 min 92%
Urine protein concentra-
α-Chymotrypsin (25 kDa)
tion
Separation of proteins
BSA (66 kDa)
and metabolites for disease
detection 30 kDa MWCO PES 8 min 96% 6 min 97%
IgG (160 kDa)

Vivaspin® Turbo 4 PES 25 pc 100 pc
3 kDa MWCO VS04T91 VS04T92
* 3,000 g (swing bucket) or 5,000 g (fixed

angle) centrifugal force for 100 kDa MWCO
devices.
Protein Concentration Centrifugal Filtration Vivaspin® Turbo 4 17

Vivaspin® 6
2 to 6 mL samples Featuring twin vertical membranes for

Vivaspin® 6 concentrators have been unparalleled filtration speeds and
developed to offer increased more than 100-fold concentration, the
volume flexibility and performance. retentate volume is easily estimated
from the printed graduations on the
Vivaspin® 6 can process an impressive side of the concentrator. The modified
6 mL in either swing bucket or fixed dead-stop pocket further simplifies
angle rotors accepting standard 15 mL direct pipette retrieval of the final
conical bottom centrifuge tubes. concentrate.
5
3 Concentrator capacity
2
1
0.5
0.3
Dimensions
0.2
122 0.1

17
Equipment Required
Centrifuge

Maximum RCF, 4,000 g 6,000 g

≥100 kDa MWCO

Performance Characteristics

Rotor Swing bucket Fixed angle (25°)
Centrifugal force 3,000 g 7,500 g
Cytochrome c 0.25 mg/mL (12.4 kDa)

3 kDa MWCO PES – – 90 min 97%


Latex beads 0.004% in DMEM + 10% FCS

(55 nm)
300 kDa MWCO PES – – 25 min 99%
Latex beads 0.004% in DMEM + 10% FCS

(240 nm)
1,000 kDa MWCO PES – – 4 min 99%
Yeast 1.0 mg/mL (S. Cerevisiae)

0.2 μm PES 4 min 97% 3 min 97%
1,000 kDa MWCO VS0661 VS0662
0.2 μm VS0671 VS0672

Vivaspin® 15R
--
--
2 to 15 mL samples Ultimate recoveries (95 – 98%)
Vivaspin® 15R is designed for initial Extremely short concentration time
sample volumes up to 15 mL and (30-fold in 15 minutes)
features a modified regenerated Simple and convenient handling
-
cellulose membrane; Hydrosart®. Easy scale-up to 0.1 to 5 L with
This membrane is ideal where Vivaflow® 50R or 200 with
extremely high recovery with very low Hydrosart® membranes
adsorption is needed. An example of Very low hold-up volume (< 20 μL)
this application includes desalting and
concentration of immunoglobulin
fractions.
15
10
5
1.0

0.75
0.5
0.3
0.15
Dimensions

30
Membrane Hydrosart® (HY)
Equipment Required
Centrifuge

20 Protein Concentration Centrifugal Filtration Vivaspin® 15R

0.15
0.3
0.5
0.75
1.0

5
10

15

0.75
0.15
0.5
0.3
1.0
10
10
15
15
5
0.75
0.15
0.5
0.3
1.0

15
10
1.0
Start volume 15 mL 12.5 mL

0.75
0.5
0.3
0.15
Spin Aprotinin 0.1 mg/mL* (6.5 kDa)

5 kDa MWCO 47 min 95% 45 min 95%
Cytochrome c 0.25 mg/mL* (12.4 kDa)

5 kDa MWCO 45 min 96% 45 min 96%
10 kDa MWCO 25 min 94% 18 min 94%
15
α-chymotrypsin 0.25 mg/mL* (25 kDa)
10 5 kDa MWCO 50 min 98% 45 min 98%
10 kDa MWCO 25 min 98% 18 min 98%
5
1.0
0.75
0.5
Ovalbumin 1.0 mg/mL* (45 kDa)

0.3
0.15
10 kDa MWCO 20 min 98% 14 min 98%

30 kDa MWCO 15 min 94% 12 min 94%
BSA 1.0 mg/mL* (66 kDa)

Recover 30 kDa MWCO 18 min 98% 15 min 98%
IgG 0.1 mg/mL in DMEM (160 kDa)

30 kDa MWCO 30 min 98% 25 min 96%
Vivaspin® 15R HY 12 pc 48 pc
2 kDa MWCO VS15RH91 VS15RH92
* Proteins other than IgG made up in 50 mM

potassium phosphate, 150 mM sodium
chloride, pH 7.4
Protein Concentration Centrifugal Filtration Vivaspin® 15R 21

Vivaspin® Endotest
2 to 15 mL samples The centrifugal design enables parallel

Vivaspin® Endotest is a single-use preparation of multiple test samples,
ultrafiltration device for endotoxin minimizing hands-on time.
concentration and removal of
interfering substan ces from liquid Vivaspin® Endotest can effectively be
samples prior to LAL testing. used in swing bucket or fixed angle
rotors accepting 50 mL conical
These devices are certified pyrogen bottom centrifuge tubes.
free (≤ 0.05 EU/mL) and are available
with 20 kDa MWCO cellulose
triacetate membranes.
15
10
5
1.0

0.75
0.5
0.3
0.15
Dimensions

30
Membrane Cellulose Triacetate (CTA)
Equipment Required
Centrifuge

Sample Mixing
Laboratory mixer Vortex
22 Protein Concentration Centrifugal Filtration Vivaspin® Endotest

0.15
0.3
0.5
0.75
1.0
Vivaspin® Endotest CTA 12 pc

5
10
15
20 kDa MWCO VS15RXETO

0.75
0.15
0.5
0.3
1.0
10
10
15
15
5
0.75
0.15
0.5
0.3
1.0
15
10
1.0
0.75
0.5
0.3
0.15
Spin
15
10
1.0
0.75
0.5
0.3
0.15
Recover
Protein Concentration Centrifugal Filtration Vivaspin® Endotest 23

Vivaspin® Turbo 15 PES
4 to 15 mL samples UV joining technology provides a

Vivaspin® Turbo 15 PES enables the smooth transition between membrane
fastest sample concentration and and housing, allowing collection of the
highest recoveries. This device can entire concentrated sample from the
handle samples up to 15 mL in rotors unique, angular dead-stop pocket.
accepting 50 mL c entrifuge tubes.
The optimized design and sleek inter- Stable polyethersulfone membranes
nal profile ensure maximum process are suited to a wide pH range and espe-
speeds all the way down to the last few cially recommended for high recovery
microlitres, resulting in more than of negatively charged target molecules.
100-fold concentration. Now complemented with a regenerat-
ed cellulose option, Vivaspin® Turbo
offers the best membrane, whatever
the sample.
Vivaspin® Turbo
1.5
118 1.0 Technical Specifications

0.5
Dimensions
30 Length x diameter 118 x 30 mm
Hold-up volume, membrane <10 μL
Dead-stop volume, swing bucket | fixed angle 100 | 60 μL
Equipment Required
Centrifuge


100 kDa MWCO
24 Protein Concentration Centrifugal Filtration Vivaspin® Turbo 15 PES



Lysozyme 0.25 mg/mL (14.3 kDa)

α-Chymotrypsin 1.0 mg/mL (25 kDa)



Vivaspin® Turbo 15 PES 12 pc 48 pc
Protein Concentration Centrifugal Filtration Vivaspin® Turbo 15 PES 25

Vivaspin® Turbo 15 RC
4 to 15 mL samples complete concentrate recovery from

Vivaspin® Turbo 15 RC enables the the unique, a
ngular dead-stop pocket.
fastest sample concentration and
highest recoveries. This device can Regenerated cellulose membranes
handle samples up to 15 mL in rotors developed specifically for Sartorius
accepting 50 mL c entrifuge tubes. lab ultrafiltration devices are suited
The optimized design and sleek to general samples, with ultra-low
internal profile ensure maximum adsorption and high chemical
process speeds all the way down to the compatibility, and especially
last few microlitres, resulting in more recommended for oligonucleotides
than 100-fold concentration. and peptides. Complemented with a
polyethersulfone option, Vivaspin®
Solvent-free, heat weld technology Turbo offers the best membrane,
provides a smooth transition between whatever the sample.
membrane and housing, allowing
Vivaspin® Turbo
1.5
118 1.0 Technical Specifications

0.5
Dimensions
30 Length x diameter 118 x 30 mm
Dead-stop volume, swing bucket | fixed angle 120 | 140 μL
Membrane Regenerated Cellulose (RC)
Equipment Required
Centrifuge


100 kDa MWCO
26 Protein Concentration Centrifugal Filtration Vivaspin® Turbo 15 RC


Centrifugal force 4,000 g* 6,000 g

5 kDa MWCO RC 23 min 94% 37 min 92%

α-Chymotrypsin 1.0 mg/mL (25 kDa)



Vivaspin® Turbo 15 RC 12 pc 48 pc
5 kDa MWCO VS15TR11 VS15TR12
* 3,000 g for 100 kDa MWCO devices
Protein Concentration Centrifugal Filtration Vivaspin® Turbo 15 RC 27

Vivaspin® 20
5 to 20 mL samples The retentate volume is easily

Vivaspin® 20 centrifugal concentrators monitored using printed graduations
have been developed to offer and the modified dead-stop pocket
increased sample and process simplifies direct retentate retrieval.
flexibility and high performance.
In addition, unique accessories are
Featuring twin vertical membra nes for available for Vivaspin® 20, enabling
high filtration speeds, Vivaspin® 20 can pressurized, ultrafiltration and
achieve in excess of 100-fold constant volume diafiltration.
concentrations factors.
15
10
5
1
0.75
116 0.5
0.2
With pressure head 15 mL
Dimensions

125 x 30 mm with pressure head

30
Pressure head Polyoxymethylene (POM) and

Aluminium (ALU)
Equipment Required
Centrifuge


≥100 kDa MWCO
Pressure
Pressure accessories VCA002, VCA005 and VCA200
Maximum pressure 5 bar (75 psi)
Maximum RCF, pressure-fuge* 3,000 g
Maximum RCF, pressure-fuge, 2,000 g

≥100 kDa MWCO*
*Swing bucket only

Equipment Required (Continued)

Mode Centrifuge Centrifuge Bench top Press-fuge
Rotor Swing bucket 25° Fixed angle Pressure Swing bucket
Centrifugal force | pressure 3,000 g 6,000 g 4 bar 3,000 g + 4 bar
Start volume 20 mL 14 mL 10 mL 10 mL
Min. Rec. Min. Rec. Min. Rec. Min. Rec.
Cytochrome c 0.25 mg/mL

(12.4 kDa)
3 kDa MWCO PES 110 97% 180 96% 60 96% – –

5 kDa MWCO PES 23 99% 29 99% 50 98% 14 98%
10 kDa MWCO PES 16 98% 17 98% 32 97% 8 97%
30 kDa MWCO PES 13 98% 15 98% 32 97% 8 97%

30 kDa MWCO PES 27 97% 20 95% 46 94% 13 97%
50 kDa MWCO PES 27 96% 22 95% 46 93% 13 96%
100 kDa MWCO PES 25 91% 20 90% 42 88% 12 94%
Latex beads 0.004% in DMEM

+10% FCS (55 nm)
300 kDa MWCO PES 20 99% 35 99% 10 99% – –

+10% FCS (240 nm)
1,000 kDa MWCO PES 4 99% 12 99% 4 99% – –

0.2 μm PES 15 95% 5 95% 20 95% 2 95%
1,000 kDa MWCO VS2061 VS2062
0.2 μm VS2071 VS2072

Vivaspin® 100
20 to 98 mL samples Vivaspin® 100 units can also be used

Vivaspin® 100 bridges the gap for single or extremely sensitive
between centrifugal concentrators samples of up to 98 mL when
and crossflow cassettes. These devices pressurized and left on the bench, or
feature vertical membranes for high for temperature-sensitive samples,
speed processing of even high particle placed into a refrigerator.
loaded samples. In addition, a unique Pressurization is made easy by use of
choice between centrifugal, pressure quick-release connectors and can be
or pressure-shake operating methods combined with orbital shaking for even
provides unrivaled process flexibility. faster sample concentration.
Fitting swing bucket rotors accepting In whichever mode Vivaspin® 100 is

250 mL bottles, Vivaspin® 100 offers used, the vertical membrane design
the highest sample capacity available inhibits membrane fouling while the
in a centrifugal device – up to an integrated dead-stop impedes
astonishing 90 mL. concentration to dryness and loss of
sample.
Device fits standard 250 mL rotors With pressure head 98 mL
Dimensions
197 x 62 mm with pressure head
Hold-up volume of membrane < 250 μL
Pressure head Polyoxymethylene (POM) and Aluminium
(ALU)
Pressure head seal Thermoplastic Elastomer (TPE)
Equipment Required
Centrifuge
Rotor type Swing bucket
Rotor cavity To fit 250 mL (60 mm) centrifuge bottles

(maximum cavity depth 105 mm)
Maximum RCF 2,000 g
Pressure
Pressure accessories VCA002, VCA800

---
Centrifuge
Process convenience
--
Pressure
Highest process
---
Pressure-shake
High process control
-
Low shear, no foaming control Ideal for single samples
Less visual control Use in fridge or cold Faster concentrations
room
Slower concentrations
Time to concentrate up to 30× at 20°C
90 mL start volume Swing bucket, Pressure, 4 bar (60 psi) Solute

2,000 g recovery
Static Orbital shake

5 kDa MWCO PES 22 min 75 min 25 min 96%


+ 10% FCS (55 nm)
300 kDa MWCO PES 35 min – 120 min 99%

+ 10% FCS (240 nm)
1,000 kDa MWCO* PES 4 min 5 min 4 min 99%
Vivaspin® 100 PES with PP cap 2 pc 10 pc
5 kDa MWCO VC1011 VC1012
30 kDaMWCO VC1021 VC1022
1,000 kDa MWCO VC1061 VC1062
0.2 μm VC1071 VC1072

Vivaspin® Equipment and Accessories
Gas Pressure Ultrafiltration Constant Volume Diafiltration
When an appropriate centrifuge is In this procedure following
unavailable, or for single sample concentration, a diafiltration cup
processing, Vivaspin® 20 and 100 inserted into the Vivaspin® 20
centrifugal concentrators may be concentrator body is filled with buffer
pressurized with compressed gas for and centrifuged once to achieve 98%
bench-top concentration. salt removal. This compares to the
need for two centrifugation steps to
For even faster processing of samples achieve the same result with the re-fill
in Vivaspin® 20, gas pressure can be and re-spin approach for
combined with centrifugal force. This discontinuous diafiltration.
pressure-fugation method is
particularly suitable for difficult to filter The improved performance is due to
or viscous samples, such as serum, or the constant washing action of the
when using low process temperatures, exchange buffer from the diafiltration
which reduce filtration speed, and cup, as it replaces the original solvent
generally when minimum process time and salts when they pass through the
is essential. In a similar way, Vivaspin® ultrafiltration membrane.
100 may be pressurized and placed on
an orbital shaker for faster processing.
0.2
0.5
0.75
1
10
15
0.75
0.75
10
15
0.5
0.2
10
0.5
15
0.2
5
5
1
1
15
10
1
0.75
0.5
0.2
15
10
Spin or stand in rack

0.75
0.5
15
0.2
10
1
0.75
0.5
0.2
15 15
10 10
Pressurize
5 5
1 1
0.75 0.75
0.5 0.5
0.2 0.2
Using the Vivaspin® 20 pressure cap
32 Protein Concentration Pressure Filration Vivaspin® Equipment

Vivaspin® Equipment and Accessories Pack Size Prod. No.

Air pressure controller (APC) fitted with pressure gauge, 1 VCA002
regulator, over-pressure safety valve and female
coupling. APCis supplied with extension line (4 mm
pneumatic tubing, 1 m) with male and female couplings,
and inlet tubing (6 mm pneumatic tubing, 1 m)
Charge valve for pressure head VCA200 1 VCA005
Female coupling 1 VCA010
Male coupling 1 VCA011
Replacement extension line 1 VCA012
(4 mm pneumatic tubing, 3 m)
Vivaspin® 20 pressure head 1 VCA200
Vivaspin 100 pressure head with seals
®
1 VCA800
Vivaspin 100 pressure head seals
®
10 VCA014
Diafiltration cups 12 VSA005
Protein Concentration Pressure Filtration Vivaspin® Equipment 33

Vivaflow® 50
0.1 to 3 L
-
Unique performance
-
The novel Vivaflow® 50 system A single 50 cm2 module will typically
provides a standard of ease of use, reduce 500 mL to less than 15 mL in
performance, flexibility and economy under 50 minutes.
--
which is unrivalled by any laboratory Less than 10 mL minimum system
or pilot scale filtration system on the recirculation for highest
-
market. concentrations.
Less than 500 μL non
Unique features recoverablehold up volume.
Thin channel flip-flow path provides Near total recoveries achievable with
--
high turbulence and cross flow a single 10 mL rinse.
velocities for exceptional flux, even at
high concentrations. Each package of two cassettes
--
No need for pressure holders. contains all of the required tubing and
Crystal clear for simple control and fittings for plug-and-play operation
visibility of membrane status. with a standard peristaltic pump
Unique interlocking modules with accepting 6.4 mm OD (size 16) tubing.
series connectors for easy scale up.
Disposable | single use.
Single cassette
Dimensions
Overall L | W | H 25 | 107 | 84 mm
Channel W | H 15 mm | 0.3 mm
Active membrane area 50 cm2
Minimum recirculation volume < 10 mL

Multiple cassettes Hold-up volume, cassette 1.5 mL
Non recoverable hold-up < 0.5 mL
Operating conditions
Pump flow rate 200 – 400 mL/min
Maximum temperature 60°C
Main housing Polycarbonate (PC)
Flow channel Polymethylpentene (PMP)

Regenerated Cellulose (RC)
Membrane support Polymethylpentene (PMP)
Seals and O rings Silicone (SIL)
Flow restrictor Polypropylene (PP)
Fittings Polyamide (PA)
Tubing Polyvinyl Chloride (PVC), medical grade
34 Protein Concentration Tangential Flow Filtration Vivaflow® 50

Time to concentrate up to 20x at 3 bar

inlet pressure, 20°C
Single device Three devices Solute recovery

250 mL 1L
Direct 10 mL rinse
start volume start volume

5 kDa MWCO PES 34 min 49 min 96% > 99%
10 kDa MWCO PES 22 min 32 min 94% > 99%
30 kDa MWCO PES 22 min 32 min 92% 99%

100 kDa MWCO RC 40 min 58 min 92% 98%

0.2 μm PES 33 min 47 min 92% 98%
Vivaflow® 50 PES 2 cassettes

3 kDa MWCO VF05P9
5 kDa MWCO VF05P1
10 kDa MWCO VF05P0
30 kDa MWCO VF05P2
50 kDa MWCO VF05P3
100 kDa MWCO VF05P4
1,000 kDa MWCO VF05P6
0.2 μm VF05P7
Vivaflow 50 RC
®
100 kDa MWCO VF05C4
Protein Concentration Tangential Flow Filtration Vivaflow® 50 35

Vivaflow® 50R
0.1 to 1 L samples Each cassette is supplied with all the

Concentrate 100 mL to under 20 mL tubing and a pressure indicator for
in just a few minutes or concentrate running the device with a laboratory
one liter 50 times in less than 60 pump and a size 16 pump head. For
--
minutes. Alternatively, speed up your speeding up concentration, two
process by using two Vivaflow® 50R cassettes can be run simultaneously.
cassettes in parallel and concentrate
--
1 liters in under 30 min. Fast and easy protein sample
concentration
Vivaflow® 50R is a plug-and-play Reusable
laboratory crossflow cassette for Concentrates volumes from
-
concentrating up to 1 L aqueous 0.1 L to 1 L
samples. The active membrane area Optimal for concentration of culture
per device is 50 cm2. supernatants and viruses
The most compact crossflow
cassette with a premium Hydrosart®
membrane
Vivaflow® 50R – Single cassette Technical Specifications

Dimensions
Overall L | W | H 24 | 100 | 100 mm
Channel W | H 7.5 | 0.4 mm
Minimum recirculation volume 10 mL
Hold-up volume, cassette 1.7 mL
Non-recoverable hold-up < 0.5 mL
Vivaflow 50R – Two cassettes
®
Pump flow rate 200 – 400 mL/min
Main housing Acrylic
Flow channel Acrylic
Membrane support Polyethylene (PE)
Seals and O-rings Silicone (SIL)
Pressure indicator Polypropylene (PP), SS spring
36 Protein Concentration Tangential Flow Filtration Vivaflow® 50R

Visit us at Typical Performance Characteristics
www.sartorius.com/
Vivaflow50R Time to concentrate up to 20× at
for further information. 3.0 bar inlet | 2.5 bar outlet pressure, 20°C
-
Here you can find Start volume Average flux Recovery
instructions on how to 250 mL mL/min
Direct 25 mL rinse
use Vivaflow® 50R for:
-
Preparation of biological
5 kDa MWCO HY 70 3.4 96% 98%
nanoparticles and medical 10 kDa MWCO HY 23 10.3 94% 96%
nanocarriers
Concentration and 10 kDa MWCO HY 24 9.9 98% >99%
purification of viruses 30 kDa MWCO HY 15 15.8 97% >99%

100 kDa MWCO HY 46 5.2 97% >99%
Start volume 1 L (one Vivaflow 50R

®
at 3 bar), BSA 1.0 mg/mL

10 kDa MWCO HY 95 10.0 98% >99%
Start volume 1 L (two Vivaflow 50R

®
in parallel at 3 bar), BSA 1.0 mg/mL

10 kDa MWCO Hydrosart® 48 19.8 98% >99%
Vivaflow® 50R HY 1 cassette

5 kDa MWCO VF05H1
10 kDa MWCO VF05H0
30 kDa MWCO VF05H2
100 kDa MWCO VF05H4
Protein Concentration Tangential Flow Filtration Vivaflow® 50R 37

Vivaflow® 200
0.5 to 5 L Each cassette is supplied complete

Concentrate 250 mL to under 20 mL with all required tubing and a pressure
in just a few minutes or concentrate indicator. All you need is a peristaltic
one litre 50 times in less than 30 pump capable of handling 6.4 mm OD
minutes. Alternatively, use two (size 16) tubing. Should your pump
Vivaflow® 200 cassettes in parallel and head require larger tubing, link your
concentrate 5 litres in under 75 own tubing up to the standard
minutes. product, using the provided stepped
hose barb connector.
Near total sample recoveries can be
expected with most solutions. Two cassettes in parallel will
concentrate 5 litres in under 75
minutes.
Dimensions
Overall L | H | W 38 | 126 | 138 mm

Vivaflow® 200 set-up for
Channel W | H 10 mm | 0.4 mm
diafiltration
Minimum recirculation volume < 20 mL
Hold up volume, cassette 5.3 mL
Non-recoverable hold-up < 2 mL
Pump flow 200–400 mL/min
Main housing Acrylic
Flow channel Acrylic

Hydrosart® (HY)
Membrane support Polypropylene
Seals and O rings Silicone (SIL)
Pressure indicator Polypropylene (PP), SS spring
38 Protein Concentration Tangential Flow Filtration Vivaflow® 200


at 3 bar inlet pressure, 20˚C
1 litre Average flux Recovery

start volume mL/min
Direct 25 mL rinse

2 kDa MWCO HY 160 6 97% > 99%
3 kDa MWCO PES 180 5 97% > 99%
Operation – Single cassette
5 kDa MWCO PES 29 33 98% > 99%
5 kDa MWCO HY 70 14 98% > 99%
10 kDa MWCO PES 23 41 96% > 99%
10 kDa MWCO HY 35 27 98% > 99%
30 kDa MWCO PES 25 38 96% 99%
30 kDa MWCO HY 20 48 96% > 99%
50 kDa MWCO PES 22 43 96% 98%
IgG 1.0 mg/mL

(160 kDa)
100 kDa MWCO PES 54 18 96% 99%

Operation – Two cassettes 0.2 μm PES 11 86 92% 98%
Dilute solute concentration, start volume

1 litre at 3 bar, 10 kDa MWCO PES
BSA 0.001 mg/mL 18 52 90% 98%
BSA 0.01 mg/mL 20 47 92% 98%
BSA 0.1 mg/mL 21 45 94% 99%
Start volume 5 litres (two VF200 in

parallel at 3 bar) 10 kDa MWCO PES
BSA 1.0 mg/mL (66 kDa) 67 70 97% > 99%
Vivaflow® 200 PES 1 cassette
3 kDa MWCO VF20P9
5 kDa MWCO VF20P1
10 kDa MWCO VF20P0
30 kDa MWCO VF20P2
50 kDa MWCO VF20P3
100 kDa MWCO VF20P4
0.2 μm VF20P7
Vivaflow 200 HY
®
2 kDa MWCO VF20H9
5 kDa MWCO VF20H1
10 kDa MWCO VF20H0
30 kDa MWCO VF20H2
100 kDa MWCO VF20H4
Protein Concentration Tangential Flow Filtration Vivaflow® 200 39

Vivaflow® Equipment
Pumps and Complete Systems transfer, in with precise flow control in

Masterflex® peristaltic pump drives and either direction. These pumps are also
heads perfectly complement Vivaflow® enabled for remote start | stop via a
crossflow cassettes, while also offering DB9 connector.
the flexibility, durability and
performance needed in multiple Loading tubing into the pump heads is
laboratory fluid transfer applications. fast and easy, thanks to the single-
With samples confined to single use thumb operated lever and automatic
tubing, there is no risk of cross- tubing retention. Each model is
contamination and no cleaning compatible with multiple tubing sizes,
required between each use. extending their suitability to further
applications, and the hard-wearing
Pump drives are offered for 230 or 115 V materials ensure long-term durability.
mains supplies. A variable speed,
reversible motor enables easy sample
Dimensions Masterflex® pump drives Easy-Load pump heads
Length x width x height 230 x 183 x 134 mm 64 x 105 x 105 mm
Weight 4.1 kg
Power output 37 W -
Speed | flow rate range 20 – 600 rpm 16 – 480 mL/min (size 16 tubing)
34 – 1,020 mL/min (size 15 tubing)
Housing Polyarylamide (PARA) Polyarylamide (PARA)
Rotor - Stainless Steel (SS) and PTFE
Rollers - Stainless Steel (SS)
Vivaflow® 50 System Pack Size Prod. No.
Pump drive (230 V), Easy-Load pump head (size 16), 500 mL 1 VFS502
diafiltration reservoir, cassette stand, spare tubing, T-connectors, series
interconnectors and pressure indicator
Pump drive (115 V), Easy-Load pump head (size 16), 500 mL diafiltration 1 VFS504
reservoir, cassette stand, spare tubing, T-connectors, series
interconnectors and pressure indicator
Vivaflow® 50R | 200 System Pack Size Prod. No.
Pump drive (230 V), Easy-Load pump head (size 16), 500 mL 1 VFS202
diafiltration reservoir, and spare tubing
Pump drive (115 V), Easy-Load pump head (size 16), 500 mL diafiltration 1 VFS204
reservoir, and spare tubing
Pump Drives and Heads Pack Size Prod. No.
Masterflex® Economy Drive variable speed peristaltic pump (230 V) 1 VFP001
Masterflex Economy Drive variable speed peristaltic pump (115 V)

®
1 VFP002
Masterflex Easy-Load pump head (Size 16)

®
1 VFA012
Masterflex Easy-Load pump head (Size 15)

®
1 VFA013
40 Protein Concentration Tangential Flow Filtration Vivaflow® Equipment

Vivaflow® Accessories
Scaling Up first concentrated to the desired

The maximum throughput or speed of volume, then a length of tubing placed
filtration with Vivaflow® cassettes can into a separate vessel containing the
be easily increased, thanks to the exchange buffer is connected to the
modular design. Up to 6x Vivaflow® 50 reservoir. Airtight sealing in the lid
cassettes can be operated in series and enables constant volume diafiltration.
parallel, while two Vivaflow® 50R or 200 As the original buffer and salts
cassettes may be run in parallel. permeate the ultrafiltration membrane,
they are replaced by an equal volume
Accessories and Replacement Parts of exchange buffer, thereby avoiding
Optional accessories such as the the large buffer volumes and possibility
diafiltration reservoir, make of sample dilution, which can be
concentration and diafiltration common to alternative methods.
exceptionally convenient. A sample is
Cassette stand Aluminium (ALU)
Luer fittings Polyamide (PA)
Flow restrictors Polypropylene (PP)
Pressure indicator Polypropylene (PP), Stainless Steel (SS), Polyoxymethylene

(POM), Silicone (SIL) and Polyamide (PA)
Diafiltration reservoir Polycarbonate (PC), Polyoxymethylene (POM), Silicone (SIL),

Polyvinyl Chloride (PVC) and Polyamide (PA)
Vivaflow® accessories for operating multiple cassettes Pack Size Prod. No.
T-connector (for 2-6x Vivaflow 50 | 2x Vivaflow 50R)

® ®
2 VFA030
Series interconnector (for 2-6x Vivaflow 50)

®
6 VFA031
Y-connector (size 15 to 2x size 16, for 2x Vivaflow 200)

®
1 VFA005
Vivaflow accessories and replacement parts

®
Vivaflow® 50 cassette stand 1 VFA016
500 mL diafiltration reservoir 1 VFA006
Pump tubing, 3 m, with luer fittings (size 16) 1 VFA004
Pump tubing, 3 m, with luer fittings (size 15) 1 VFA003
Female Luer lock to hose barb fittings (size 16) 10 VFA032
Female Luer lock to hose barb fittings (size 15) 10 VFA036
Flow restrictors, 0.6 mm 6 VFA035
Flow restrictors, 0.4, 0.6 and 0.8 mm (2 of each) 6 VFA009
Pressure indicator (1-3 bar) 1 VFA020
Vivaflow® tubing set (2x 1 m feed tubing with Luer fitting, 2x 0.5 m 1 VFA034
retentate tubing with flow restrictor, 1x series interconnector)
Protein Concentration Tangential Flow Filtration Vivaflow® Accessories 41

Ultrafiltration Membrane Discs
Polyethersulfone (PES) membrane support that could trap or

This is a general purpose membrane bind passing microsolutes, these
that provides excellent performance membranes are preferred for sample
with most solutions when high cleaning, protein removal, and when
recoveries in the retentate are of high recoveries from the filtrate are of
primary importance. Polyethersulfone primary importance.
membranes exhibit no hydrophobic
or hydrophillic interactions and are Hydrosart® (HY)
usually preferred for their low fouling These membranes are also highly
characteristics, exceptional flux and hydrophillic and are often preferred
broad pH compatibility. for their higher protein recovery
when processing very dilute solutions.
Cellulose Triacetate (CTA) Resistance to autoclaving, ease of
High hydrophilicity and very low non- cleaning and extended chemical
specific binding characterize this compatibility also characterize this
membrane. Cast without any membrane material.
Technical Specifications and Typical Performance
Polyethersulfone, Type Cellulose Triacetate, Hydrosart®, Type 144

146 Type 145
Thickness 120 μm 120 μm 180 μm
pH range 1 – 14 4–8 1 – 13
Flux with water
10 kDa MWCO 0.2 mL/min/cm2 0.11 mL/min/cm2 0.08 mL/min/cm2
Protein retention
Cytochrome c 95% 90% 99%
PES Membrane Discs, Type 146 Diameter 10 pc
1 kDa MWCO 47 mm 14609--47------D
63 mm 14609--63------D
76 mm 14609--76------D
5 kDa MWCO 25 mm 14629--25------D
47 mm 14629--47------D
63 mm 14629--63------D
76 mm 14629--76------D
10 kDa MWCO 25 mm 14639--25------D
43 mm 14639--43------D
47 mm 14639--47------D
63 mm 14639--63------D
76 mm 14639--76------D
150 mm 14639-150------D
42 Protein Concentration Ultrafiltration Membrane Discs

PES Membrane Discs, Type 146 (con't) Diameter 10 pc
30 kDa MWCO 25 mm 14659--25------D
47 mm 14659--47------D
63 mm 14659--63------D
76 m 14659--76------D
50 kDa MWCO 25 mm 14650--25------D
47 mm 14650--47------D
76 mm 14650--76------D
100 kDa MWCO 47 mm 14668--47------D
63 mm 14668--63------D
300 kDa MWCO 25 mm 14679--25------D
47 mm 14679--47------D
76 mm 14679--76------D
CTA Membrane Discs, Type 145
5 kDa MWCO 25 mm 14529--25------D
47 mm 14529--47------D
10 kDa MWCO 25 mm 14539--25------D
47 mm 14539--47------D
50 mm 14539--50------D
20 kDa MWCO 25 mm 14549--25------D
43 mm 14549--43------D
47 mm 14549--47------D
63 mm 14549--63------D
HY Membrane Discs, Type 144
2 kDa MWCO 47 mm 14419--47------D
63 mm 14419--63------D
5 kDa MWCO 25 mm 14429--25------D
44 mm 14429--44------D
47 mm 14429--47------D
63 mm 14429--63------D
76 mm 14429--76------D
10 kDa MWCO 25 mm 14439--25------D
47 mm 14439--47------D
63 mm 14439--63------D
76 mm 14439--76------D
30 kDa MWCO 25 mm 14459--25------D
47 mm 14459--47------D
63 mm 14459--63------D
76 mm 14459--76------D
100 kDa MWCO 47 mm 14468--47------D
Protein Concentration Ultrafiltration Membrane Discs 43

DNA Concentration
Table of Contents
Vivacon® 500 46
Vivacon® 2 49
45
Vivacon® 500
100 to 500 μL samples Vivacon® 500 PCR Grade

Vivacon® 500 centrifugal When using DNA amplification
concentrators offer the optimal technologies, any traces of DNA
solution for DNA and protein originating from the equipment have
concentration and buffer exchange to be eliminated.
applications. For optimal performance
with very dilute samples, e.g. forensic Vivacon® 500 PCR Grade units are
samples, Vivacon® 500 is equipped treated with ethylene oxide (ETO)
with the patented regenerated in a validated process in order to
cellulose membrane, Hydrosart®. deactivate all traces of DNA that
might interfere with subsequent
High recoveries and excellent amplification procedures.
reproducibilities are paired with
convenience offered by molecular Ref.: K. Shaw et al., Int. J. Legal Med.
weight cut-off printed on individual (2008) 122: 29–33
devices.
The possibility of a reverse-spin after

sampleprocessing assures complete
concentrate recovery which is
especially important when working
with low sample concentrations.
Feature Benefit
Reverse-spin enabled Complete and highly reproducible

sample recovery
Low binding material High recoveries of low sample concentrations
Reverse spin
Dimensions
Length x diameter 45 x 12.4 mm

47.5 x 12.4 mm reverse spin
Hold-up volume, of membrane and support < 5 μL
Dead-stop volume (40° rotor) 5 μL

Cellulose Acetate (CA)
46 DNA Concentration Vivacon® 500

Conversion Table for MWCO to Nucleotide Cut-Off
Membrane Single-Stranded Double-Stranded

Cut-Off (SSCO) Cut-Off (DSCO)
2 kDa HY > 10 bases > 10 bp
100 kDa HY > 900 bases > 600 bp
125 kDa CA > 1,000 bases > 650 bp
Typical Performance Characteristics for DNA

Start volume 0.5 mL, sample concentration 50 ng/mL
MWCO Nucleic Acid Time to Concentrate up Concentrate RCF

Length to 30× at 20°C Recovery
2 kDa 10 bp 60 min 93% 7,500 g
10 kDa 30 bp 25 min 94% 7,500 g
30 kDa 50 bp 18 min 88% 5,000 g
50 kDa 300 bp 18 min 91% 5,000 g
100 kDa 600 bp 10 min 87% 3,000 g
125 kDa 650 bp 12 min 85% 2,000 g
125 kDa 900 bp 9 min 94% 3,000 g
Typical Performance Characteristics for Proteins

Start volume 0.5 mL, sample and concentration of proteins as specified in table
MWCO Test Molecule Time to Concentrate up Concentrate RCF

to 30× at 20°C Recovery
2 kDa 0.25 mg/mL 30 min 95% 14,000 g

cytochrome c
10 kDa 0.25 mg/mL 15 min 92% 14,000 g

cytochrome c
30 kDa 1.0 mg/mL BSA 10 min 95% 14,000 g
50 kDa 1.0 mg/mL BSA 10 min 92% 14,000 g
100 kDa 1.0 mg/mL 11 min 90% 8,000 g

bovine IgG
125 kDa 1.0 mg/mL 10 min 81% 8,000 g

bovine IgG
DNA Concentration Vivacon® 500 47

Vivacon® 500 25 pc 100 pc 500 pc
2 kDa MWCO VN01H91 VN01H92 -
30 kDa MWCO VN01H21 VN01H22 VN01H23
Vivacon® 500 PCR

Grade
30 kDa MWCO - VN01H22ETO VN01H23ETO
100 kDa MWCO - VN01H42ETO -
Vivacon® 500 Accessories
Additional collection tubes, 100 pc VNCT01

Vivacon® 2
0.4 – 2 mL samples The possibility of a re-spin after sample

Vivacon® 2 centrifugal concentrators processing assures complete con
offer the optimal solution for DNA centrate recovery which is especially
and protein concentration and buffer important when working with low
exchange applications. For optimal sample concentrations.
performance with very dilute samples,
e.g. forensic samples, Vivacon® 2 is Vivacon® 2 PCR Grade
equipped with the patented regener- Vivacon® 2 PCR Grade units are
ated cellulose membrane Hydrosart®. treated with ethylene oxide (ETO)
in a validated process in order to
High recoveries and excellent repro- deactivate all traces of DNA that
ducibilities are paired with conve- might interfere with subsequent
2.0
mL
nience offered by volume graduation amplification procedures.
and molecular weight cut-off printed
1.5
1.0
on individual devices.
Feature Benefit
Re-spin possibility Complete and highly reproducible

sample recovery
Low binding material High recoveries of low sample concentration
1.0
Easy to remove re-spin cap Convenient sample handling
Graduation printed on Optimal process control

1.5
mL
2.0

Reverse spin
Dimensions

115 x 16 mm reverse spin
Hold-up volume, membrane and support 10 μL
Dead-stop volume (25° rotor) 55 μL
Reverse-spin recovery vial Polypropylene (PP)
Recovery vial cap Polypropylene (PP)

Cellulose Acetate (CA)

Conversion Table for MWCO to Nucleotide Cut-Off
Membrane Single-Stranded Double-Stranded

Cut-Off (SSCO) Cut-Off (DSCO)
100 kDa HY > 900 bases > 600 bp
125 kDa CA > 1,000 bases > 650 bp
Typical Performance Characteristics for DNA

Volume 2 mL, sample concentration 50 ng/mL, start volume: 2 mL
MWCO Nucleic Acid Time to Concentrate up Concentrate RCF

Length to 30× at 20°C Recovery
2 kDa 10 bp 120 min 92% 7,500 g
10 kDa 30 bp 60 min 94% 5,000 g
30 kDa 50 bp 60 min 95% 2,500 g
50 kDa 300 bp 45 min 96% 2,500 g
100 kDa 600 bp 30 min 93% 2,500 g
125 kDa 650 bp 30 min 88% 2,500 g
125 kDa 900 bp 30 min 89% 2,500 g
Typical Performance Characteristics for Proteins

Start volume 2 mL, sample and concentration of proteins as specified in table
MWCO Test Molecule Time to Concentrate up Concentrate RCF

to 30× at 20°C Recovery
2 kDa 0.25 mg/mL 120 min 95% 7,500 g

cytochrome c
10 kDa 0.25 mg/mL 90 min 96% 5,000 g

cytochrome c
30 kDa 1.0 mg/mL BSA 40 min 96% 5,000 g
50 kDa 1.0 mg/mL BSA 30 min 94% 5,000 g
100 kDa 1.0 mg/mL 30 min 92% 5,000 g

bovine IgG
125 kDa 1.0 mg/mL 27 min 81% 5,000 g

bovine IgG

Vivacon® 2 25 pc 100 pc 500 pc
Vivacon® 2 PCR Grade
125 kDa MWCO - - VN02H83ETO

Protein Purification
Table of Contents
Vivaclear Centrifugal Filters 54
Vivapure® Ion Exchange Purification Products 56
53
Vivaclear Centrifugal Filters
Vivaclear centrifugal filters are dispos-
-
Applications
---
able microfiltration devices for the fast Clarification of samples before
and reliable clarification or filtration of loading onto Vivapure® protein
biological samples in the range 100 t o purification spin columns
500 μL. They can be used in fixed Removal of particles and participates
angle rotors accepting 2.2 mL centri- Filtration of plasma and serum
--
fuge tubes. Removal of cells or cell debris
Product Features
--
High-flux polyethersulfone
membrane
0.8 μm pore size
Low hold-up volume (< 5 μL)
Fast and reproducible performance
54 Protein Purification Vivaclear Centrifugal Filters

Filter capacity
Swing bucket rotor do not use
Fixed angle rotor 500 μL
Dimensions
Hold-up volume, membrane and support < 5 μL
Body Polypropylene (PP)
Filtrate tube Polypropylene (PP)
Equipment Required
Centrifuge
Rotor type Fixed angle (40-45°)
Rotor cavity To fit 2.2 mL (11 mm) conical bottom tubes
Maximum RCF 2,000 g
Filtrate recovery
Pipette type Fixed or variable volume
Recommended tip Standard type
Vivaclear Mini 100 pc
0.8 μm PES VK01P042
Protein Purification Vivaclear Centrifugal Filters 55

Vivapure® Ion Exchange Purification Products
Fast and easy-to-use spin columns The microporous structure of these

Vivapure® Ion Exchange (IEX) devices membrane adsorbers has a pore size
incorporate Sartobind® membrane > 3 μm, which is orders of magnitude
adsorber technology as the larger than conventional
chromatography matrix. The ready-to- chromatography resins. This allows
use spin column format makes protein molecules to be transported to the
purification as easy as filtration. With ligands immobilized on the membrane
no risk of running dry, Vivapure® adsorber by convective flow,
replaces time-consuming and overcoming the diffusion limitations of
SEM comparing chromatography expensive r esin-based chromatography resins, and leading to
beads (right) with the Sartobind® chromatography in many protein very high flow rates. The large pore
membrane adsorber, which fea-
purification workflows. sizes also prevent gel filtration effects
tures 50x larger pore sizes.
and minimize non-specific binding.
The rapid bind-wash-elute protocol is
especially ideal in screening With Vivapure®, there is no need for
applications, where multiple samples column packing, saving time and
or purification conditions can be ensuring reproducibility. Furthermore,
conveniently processed in parallel. Sartobind® membrane adsorber
technology is available in process scale
formats, making Vivapure® an
indispensible tool for process
development prior to purification
scale-up.
Spin Spin
Original Protein is bound Wash Elute Pure

sample to membrane protein
Fast and easy protein purification with Vivapure® spin columns
56 Protein Purification Vivapure® Ion Exchange Protein Purification Products

Membrane Availability
Functional groups Ion exchanger type
Sulphonic acid (S) Strong acidic cation exchanger: R-CH₂-SO₃-Na+
Quaternary ammonium (Q) Strong basic anion exchanger: R-CH₂-N+-(CH₃)₃Cl-
Diethylamine (D) Weak basic anion exchanger: R-CH₂-NH+-(CH₂H₅)₂

Vivapure® Mini H
Vivapure® spin Protein binding Max. volume, Max. volume,
columns capacity* swing bucket fixed angle
Vivapure® Mini H 4 mg – 0.4 mL
Vivapure Maxi H
®
60 – 80 mg 19 mL 10.5 mL
---
Typical Applications
--
Fractionation of protein mixtures prior to 1D or 2D-PAGE
Scouting purification conditions for new protein targets
Removal of endotoxins from monoclonal antibodies
---
Vivapure® Maxi H Preparation of heme moiety from heme containing protein prior to functional
analysis
General protein purification and polishing
-
Detergent removal from protein solutions
Purification of antibodies from serum, ascites or cell culture supernatant
Intermediate sample purification prior to further HPLC | FPLC
Purification of membrane-bound proteins
Detailed application notes are available on our website: www.sartorius.com
Vivapure® Mini H Ordering Information
Vivapure® Mini Spin Centrifuge Prod. No.

Columns Tubes
Vivapure® D Mini H 24 48 VS-IX01DH24
Vivapure Q Mini H
®
24 48 VS-IX01QH24
Vivapure S Mini H
®
24 48 VS-IX01SH24
Vivapure Maxi
®
Vivapure® D Maxi H 8 16 VS-IX20DH08
Vivapure Q Maxi H
®
8 16 VS-IX20QH08
Vivapure® Maxi H
Vivapure S Maxi H
®
8 16 VS-IX20SH08
* Binding capacities established using

1 mg/mL BSA in 25 mM Tris-HCl (pH 8) for
Vivapure® Q and D devices, or 1 mg/mL
cytochrome c in 25 mM sodium acetate
buffer (pH 5.5) for Vivapure® S devices.
Actual capacities depend on the target
molecule and selected buffer conditions.
Protein Purification Vivapure® Ion Exchange Protein Purification Products 57

Virus Purification and
Concentration
Table of Contents
Vivapure® Virus Purification and Concentration Kits 60
Adenovirus Purification 61
Lentivirus Purification 66
59
Vivapure® Virus Purification and Concentration Kits
Recombinant virus vectors are the Rapid Virus Purification by

preferred method for a wide range of Membrane Chromatography
gene delivery applications. Especially The Sartobind® ion exchange
adenovirus type 5 and VSV-G membrane adsorber technology used
pseudotyped lentivirus are two in Adenopack and Lentiselect is
frequently utilized viral vectors for in unique in its capability to efficiently
vitro and in vivo applications. and rapidly capture and recover large
virus particles. When compared to
Recombinant Adenovirus Vectors chromatography media, membrane
Recombinant adenovirus vectors are adsorbers provide large 3000 nm
versatile tools in research and pores allowing unrestricted access
therapeutic applications for gene and recovery of virus from the charged
transfer and protein expression in cell adsorber surface. Convective flow
lines that have low transfection through the syringe filter devices
efficiency with liposomes. provides high-speed separations not
possible with traditional
After entering cells, the virus remains chromatography, cesium chloride
epichromosomal (i.e. does not density gradients and
integrate into the host chromosome, ultracentrifugation methods.
leaving the host genome unaffected).
The delivery of RNAi into cells is Our membrane adsorbers with porous
becoming a major application for matrices, high capacities, low differ
adenovirus vectors. ential pressures, high flow rates and
low unspecific adsorption show an
Lentivirus Vectors excellent performance in small scale
Lentivirus vectors are frequently used virus purification. Additionally, they
in gene transfer studies, due to their are also scalable and confirm to
ability of gene transfer and integration cGMP facilities to large volume, high
into dividing and non-dividing cells. performance separation, reducing
The pseudotyped envelope with the processing time by a factor of 10
vesicular stomatitis virus envelope G in the final process.
(VSV-G) protein broadens their target
cell range. Lentiviral vectors have been
shown to deliver genes into cell types
(e.g. neurons, lymphocytes and
macrophages) which other retrovirus
vectors could not be used for. The
lentivirus vector is increasingly used
to integrate siRNA efficiently in a wide
variety of cell lines and primary cells,
both in vitro and in vivo.
60 Virus Purification and Concentration Vivapure® Virus Purification and Concentration Kits
Adenovirus Purification
--
Adenopack 20 | 100 | 500 Adenopack Advantages
The Adenopack adenovirus purifi
cation and concentration kits offer Fast and Easy Virus Purification
researchers who need to recover up to Purification completed in 2 hours
3 × 1013 purified recombinant adeno Convenient, over 10 × faster
-
virus particles for invitro transfection a alternative to CsCl density gradient
fast, safe and easy to use solution. The
kits include all reagents and devices Quantitative Yields
necessary for clarification, purification In contrast to CsCl density gradient,
and concentration of adenovirus the complete cell culture is used for
type 5 from HEK293 cell cultures in virus purification and not only the
-
only two hours. These straight forward viral pellet
kits replace time-consuming and
labor-intensive 48 hour CsCl density Flexible Product Range
gradients. Applicable from initial construct
screening to large scale virus
-
Adenopack kits are offered as production
Adenopack 20, Adenopack 100
and Adenopack 500, for the Complete Kit
purification and concentration of Including filtration devices,
adenovirus type 5 from 20 mL to Adenopack units for virus purifica-
-
500 mL cell culture, leading to tion, Vivaspin® and all buffers
1 × 1011- 3 × 1013 purified viral particles.
For each sample volume, the most Low Endotoxin Levels
convenient handling method is High cell viability and infection
offered for ultimate convenience. rates due to endotoxin levels of
< 0.025 EU/mL
To this end, preparations using
Adenopack 20 are pursued in
spin column format in a centrifuge,
Adenopack 100 is a manually
operated kit in syringe filter format*,
and Adenopack 500 is a pump
driven kit.
Purification of GFP-Ad5 Constructs
Purification method Process time Eluate Recovery*** Viral Particles
Adenopack 20 | 20 mL culture 1 hour 1 mL 65 – 70% 1 × 1011-12
Adenopack 100 | 60 mL culture 1 – 2 hours 1 mL 65% 1 – 3 × 1012
Adenopack 100 | 200 mL culture 2 hours 1 mL 80% 1 × 1013
Adenopack 500 | 500 mL culture 2 hours 1 mL 80% 1 – 3 × 1013
500 mL CsCl density gradient 24 – 48 hours 1 – 2 mL** 60 – 70% 1 × 1011-12
* Vivapure® Adenopack 100 can optionally

be operated with a laboratory pump and an
infusion pump, for which protocols are pro-
vided on our web page www.sartorius.com.
Additionally, the tubes and adaptors needed
for these operation modes can be ordered.
** after dialysis
*** before buffer exchange
Virus Purification and Concentration Adenovirus Purification with Vivapure® Adenopack Kits 61
Vivapure® Adenopack 20
The optimal kit for construct screening
Vivapure® Adenopack 20 is the in the CsCl density gradient method –

downscale kit in the Adenopack for the first time adenovirus type 5 can
series, purifying up to 1 × 1012 adeno efficiently be purified from less than
virus type 5 particles from 20 mL cell 100 mL cell culture volume!
culture. Especially when testing new
constructs, parallel and fast Typical Performance
purifications of different adenoviruses For a normal yielding vector, 1 × 15 cm
are essential. This kit allows the rapid, culture plate purified using this
simple and affordable spin column method yields up to 1 × 1012 viral
based purification of 6 different particles.
samples in parallel and bridges a gap
Ordering Information and Kit Contents
Vivapure® Adenopack 20 VS-AVPQ020

Vivapure Adenopack 20 RT*
®
VS-AVPQ022
Adenopack Maxi spin columns 6
Vivaclear Maxi 0.45 μm PES 6
Empty 50 mL tubes 6
Loading Buffer (10×) 25 mL
Washing Buffer (10×) 30 mL
Elution Buffer 20 mL
Benzonase (12.5 U/μL)
®
120 μL
Vivaspin 20, 100 kDa MWCO
®
6
Instructions 1 each for Kit and Vivaspin®
Technical Data
Kit specifications
Sample size 20 mL of cell culture
Number of purifications 6 × 20 mL
Virus particles (VP) per mL Typically up to 1 × 1011 – 1012
VP | IU 50–100
Processing time Typically 1 hour
Endotoxin level < 0.025 EU/mL
spin spin spin
* A denopack 20 RT does not include

Benzonase®
** Benzonase® Nuclease is manufactured by
Merck KGaA, Darmstadt, Germany and
is covered by US Patent 5,173,418 and EP
Patent 0,229,866. Nycomed Pharma A/S 1. Treat with Benzonase®** 5. Bind virus and wash 6. Elute purified virus Final
(Denmark) claims worldwide patent rights 2. Filter with Vivaclear Maxi away contaminants concentration|
to Benzonase® Nuclease, which are licensed 3. Add 10× Loading Buffer buffer exchange
exclusively to Merck KGaA, Darmstadt, to sample
Germany. Benzonase® is a registered trade- 4. Equilibrate Adenopack Maxi spin columns
mark of Merck KGaA, Darmstadt, Germany.
62 Virus Purification and Concentration Vivapure® Adenopack 20

Fast purification of up to 1 × 1013 viral particles
Vivapure® Adenopack 100 is optimally However, for even more convenience,

suited for adenovirus purification from protocols are provided for optionally
up to 200 mL cell culture for in vitro running the virus purification with a
transfection. This flexible kit contains peristaltic pump or with an infusion
two Adenopack 100 units, which pump, in additional to detailed
can be either used in tandem for the instructions for a manual operation
purification of up to 200 mL cell supplied with the kit. The accessories
culture for recovering 1 × 1013 viral needed for the operation with a pump
particles or individually for purifying are supplied as individual products.
1–3 × 1012 viral particles from up to
60 mL cell culture. The purification Typical Performance
is pursued manually with a syringe For a normal yielding vector, 10 × 15 cm
optimally attached to a retort stand. culture plate purified using this
method yields up to 1 × 1013 viral
particles.

®
VS-AVPQ102
Adenopack 100 units 2
Minisart NML Plus

®
4
20 mL syringe 4
Tubing set and one way valve 2
10 mL syringe (elution) 2
Loading Buffer (10×) 1 × 25 mL
Washing Buffer 1 × 120 mL
Elution Buffer 1 × 20 mL
Benzonase 12.5 U/μL

®
200 μL
Vivaspin 20 concentrator
®
4
Adenopack 100 Accessories
Pump tubing set for Vivapure® Adenopack 100 VS-AVPA001
* Adenopack 100 RT does not include

Benzonase®
Virus Purification and Concentration Vivapure® Adenopack 100 63

Technical Data
Kit specifications
Sample size 20–200 mL of cell culture
Number of purifications 2 × 20–60 mL
1 × 200 mL
Virus particles (VP) per mL Typically up to 1 × 1013
VP | IU 20–50
Processing time Typically 2 hours
1. Add Benzonase® 2. Load cleared 3. Wash 4. Elute Concentrate

and clarify sample sample
64 Virus Purification and Concentration Vivapure® Adenopack 100

Pump driven kit for larger volumes
Vivapure® Adenopack 500 is the to use product replaces lengthy and

direct upscale kit to the Adenopack inefficient cesium chloride density
100, for adenovirus purification. In gradient methods.
only 2 hours up to 3 × 1013 adenovirus
particles are purified and concentrated Typical Performance
from 500 mL cell culture. This For a normal yielding vector, 25 × 15 cm
completely ready-to-use kit is culture plate purified using this
conveniently operated by a laboratory method yields up to 3 × 1013 viral
pump, offering optimal flow control particles.
and minimal hands-on time. This easy

®
VS-AVPQ502
Adenopack 500 unit 1
Sartopore 2 150
®
1
Tubing set and one way valve 2
10 mL syringe 1
Loading Buffer (10×) 60 mL
Washing Buffer (10×) 30 mL
Elution Buffer 20 mL
Benzonase® 12.5 U/μL 500 μL
Vivaspin 20 concentrator
®
2
Technical Data
Kit specifications
Sample size 500 mL of cell culture
Virus particles (VP) per mL Typically up to 3 × 1013
VP | IU 20–50
Processing time Typically 2 hours
1. Add Benzonase® and 2. Load sample and wash 3. Elute 4. Concentrate

* Adenopack 500 RT does not include clarify sample unspecifically bound proteins
Benzonase®
Virus Purification and Concentration Vivapure® Adenopack 500 65

Lentivirus Purification
-
Lentiselect 40 | 500 | 1000 Lentiselect Advantages
The Lentiselect lentivirus purification
and concentration kits offer Fast and Easy Virus Purification
-
researchers who need to recover up to Purification completed in under one
5 × 109 infective lentivirus particles per to six hours, depending on sample
mL for invitro transfection or animal volume
-
studies a fast and easy to use solution. Kit as easy to use as filtration
These straight forward kits replace No Need for Expensive Instruments

time-consuming ultracentrifugation Lentivirus purification with
protocols, which typically take Lentiselect is independent of
-
approximately one day for large sample equipment such as ultracentrifuges
volumes, thus reducing the purification
time to only a few hours. High Virus Purity
Achieve pure virus due to a
Lentiselect kits are offered as chromatography purification for your
Lentiselect 40, Lentiselect 500 and experiments instead of a crude and
Lentiselect 1000 for the purification variable cell culture supernatant
and concentration of VSV-G pellet
-
pseudotyped lentivirus from 40 mL to 1
L cell culture, leading to 8 × 108 – 1 × 1010 Optimal for Multiple Virus Construct
purified infective particles. For each Screening
sample volume, the most convenient With Lentiselect 40, four purification
handling method is offered. To this runs can be conducted in parallel
-
end, 40 mL sample volumes are with one kit
processed manually with Lentiselect
40, while Lentiselect 500 and 1000 Complete Kits
are pump driven kits. Including Lentiselect units for
virus purification, Vivaspins for
concentration | buffer exchange and
-
all buffers and syrings necessary
Low Endotoxin Levels

High cell viability and infection
rates due to endotoxin levels of
< 0.025 EU/mL
Purification of VSV-G Pseudotyped Lentivirus Constructs
Purification method Process Eluate Viral Recovery Infective Viral

time Particles/mL Particles
Lentiselect 40 45 min 200 μL* 4 × 109 50% 8 × 108

40 mL sample
Lentiselect 500 3 hours 1 mL* 3 × 109 35% 2 – 5 × 109

500 mL sample
Lentiselect 1000 6 hours 2 mL* 5 × 109 35% 1 × 1010

1 L sample
Ultracentrifugation 10 – 11 hours 500 μL 6 × 109 25% 3 × 109

500 mL sample
* After desaltin | buffer exchange
66 Virus Purification and Concentration Lentivirus Purification with Vivapure® Lentiselect Kit
Vivapure® Lentiselect 40
Fast purification of up to 8 × 108 viral particles
Vivapure® Lentiselect 40 is optimally centrifuge. Additionally, this

suited for lentivirus purification for up chromatographic procedure leads to
to 40 mL cell culture and contains all pure virus samples in contrast to the
components necessary for 4 crude ultracentrifuge pellet, resulting
purifications. Up to 8 × 108 viral in higher reproducibility and increased
particles are recovered in less than gene transfer efficiency.
one hour. In contrast to traditional
ultracentrifugation methods, virus Typical Performance
purification with Vivapure® Lentiselect For a normal yielding vector, 2 × 15 cm
is fast and simple, without the need for culture plate purified using this
expensive equipment like an ultra method yield up to 8 × 108 particles.
Vivapure® Lentiselect 40 VS-LVPQ040

Lentiselect unit 4
50 mL syringe 4
10 mL syringe 4
Tube set with one-way valve 4
Loading buffer (10 ×) 30 mL
Washing buffer 150 mL
Elution buffer 20 mL
®
8
Technical Data
Kit specifications
Sample size 40 mL cell culture
Infective particles (P) per mL Typically up to 3 × 109
VP | IU 5 – 15
Processing time Typically 45 minutes
10 mL syringe
containing
elution buffer
Lentiselect
Unit
Lentiselect
Unit
Purified virus
Tube containing
24 mL buffer
1. 2. Washing 3. Elute
Virus Purification and Concentration Vivapure® Lentiselect 40 67

Fast purification of up to 2–5 × 109 infective particles per mL from 500 mL cell culture
Vivapure® Lentiselect 500 is optimally Vivapure® Lentiselect 500 offers

suited for VSV-G pseudotyped lenti a fast and simple solution for purifying
virus purification from up to 500 mL VSV-G pseudotyped lentiviruses
cell culture and contains all reagents making expensive purification
and devices necessary for purifying up equipment like ultracentrifuges
to 2–5 × 109 infective particles. redundant.
The whole purification procedure Typical Performance

is simply operated by a laboratory For a normal yielding vector, 500 mL
pump, which minimizes hands-on cell culture purified using this method
time. Unlike conventional purification yield up to 2–5 × 109 infective particles
methods as ultracentrifugation, per millilitre (total volume 1 mL).

Lentiselect unit 1
Sartopore 2 150 ®
1
50 mL syringe 1
®
2
Operating manual 1 each for Kit and Vivaspin®
Technical Data
Kit Specifications
Sample volume 500 mL cell culture
Infective particles (IP) per mL Typically up to 2–5 × 109*
Processing time Typically up to 3 hours
1. Filter 2. Add Loading Buffer 5. Elute purified virus

3. Prepare Lentiselect Unit 6. Concentrate and exchange
4. Bind virus an d wash away contaminants buffer using Vivaspin®
* 1 mL final elution sample
68 Virus Purification and Concentration Vivapure® Lentiselect 500

Pump driven kit for larger sample volumes
Vivapure® Lentiselect 1000 is the devices for optimal convenience. The

direct scale up kit to Lentiselect 500, traditional time consuming
for VSV-G pseudotyped lentivirus ultracentrifugation method is replaced
purification. The rapid 6 hour protocol by this fast and simple Vivapure®
results in a recovery of 4–5 × 109 Lentiselect 1000 kit.
infective particles per mL (total volume
2 mL) from 1 L cell culture supernatant. Typical Performance
For a normal yielding vector, 1 L cell
This kit is to be operated by a culture purified using this method
laboratory pump and contains all yield up to 4 – 5 × 109 infective particles
necessary buffers and ultrafiltration per millilitre (total volume 2 mL).

Lentiselect unit 2
Sartopore® 2 150 1
50 mL syringe 1
®
2
Operating manual 1 each for Kit and Vivaspin®
Technical Data
Kit specifications
Sample volume 1 L cell culture
Number of purifications 1×1L
Infective particles (IP) per mL Typically up to 4 – 5 × 109*
Processing time Typically up to 6 hours
1. Filter 2. Add Loading Buffer 5. Elute purified virus

3. Prepare Lentiselect Units 6. C
oncentrate and exchange
4. Bind virus and wash away contaminants buffer using Vivaspin®
* 2 mL final elution sample
Virus Purification and Concentration Vivapure® Lentiselect 1000 69

Application Notes
Table of Contents
1. Desalting and Buffer Exchange with Vivaspin® Centrifugal

Concentrators 72
2. Treatment of Vivaspin® Concentrators for Improved Recovery

of Low-concentrated Protein Samples 75
3. Scouting Protein Purification Conditions Using Vivapure® Centrifugal

Ion Exchange Membrane Absorbers 78
4. Concentration and Purification of Viruses by using Ultrafiltration,

Incl. Coronavirus – a Short Review 83
5. Sartorius Ultrafiltration Products in the Preparation of Biological

Nanoparticles and Medical Nanocarriers 95
6. Vivaflow® and Vivaspin® Workflow in Protein Research Laboratories 101
71
1. Desalting and Buffer Exchange with Vivaspin®
Centrifugal Concentrators
Introduction The protein sample can then be
Vivaspin® centrifugal concentrators, concentrated again to the desired
with patented vertical membrane level, or the buffer exchange can be
technology, combine fast filtration repeated to reduce the salt
with high recovery of target proteins. concentration even further before a
This makes Vivaspin® the technology final concentration of the protein. This
of choice for desalting or buffer process is called diafiltration. For
exchange, avoiding lengthy dialysis proteins with a tendency to precipitate
steps. at higher concentrations, it is possible
to perform several diafiltration steps in
While proteins are retained by an sequence, with the protein
ultrafiltration membrane, salts can pass concentrated each time to only 5 or
freely through, independent of protein 10×. For example, if a precipitous
concentration or membrane MWCO. protein sample is concentrated to 5×
In consequence, the composition of then diluted back to the original
the buffer in the flow-through and volume, and this process is repeated a
retentate is unchanged after protein further two times, this still results in a
concentration. By diluting the >99% reduction in salt concentration,
concentrate back to the original without over-concentrating the
volume, the salt concentration is protein.
lowered. The concentrate can be
diluted with water or salt-free buffer if
simple desalting is required; however,
it is also possible to dilute the
concentrate with a new buffer, thereby
exchanging the buffering substance
entirely. For example, a 10 mL protein
sample containing 500 mM salt, if
concentrated 100-fold still contains
500 mM salt. If this concentrate is
then diluted 100× with water or salt-
free buffer, the protein concentration
returns to the original level, while the
salt concentration is reduced 100× to
only 5 mM (i.e. a 99% reduction in salt
concentration).
72 Application Notes 1. Desalting and Buffer Exchange with Vivaspin®

Methods 2. Centrifuge for the recommended
Select an appropriate MWCO for your amount of time at an appropriate
sample. For maximum recovery, select spin speed (see device operating
a MWCO ⅓ to ½ the molecular weight instructions).
of the molecule of interest. 3. Empty filtrate container and refill the
concentrator with an appropriate
1. Add protein sample up to the maxi- exchange solvent.*
mum fill volume of the concentrator 4. Centrifuge again as before.
(as stated in the device operating 5. Recover the concentrated, desalted
instructions). If the sample volume sample from the bottom of the
is lower than the maximum device concentrate pocket with a pipette.
volume, it can be diluted to the
maximum fill volume before the first
centrifugation step. This will increase
the salt removal rate.
1 2 3 4 5
Figure 1: Step-by-step method for desalting and concentration
* Filtrate volumes should be retained until the

concentrated sample has been analyzed.
Application Notes 1. Desalting and Buffer Exchange with Vivaspin® 73

Results
Vivaspin® 20
MWCO 5 kDa 30 kDa 50 kDa 100 kDa
Cytochrome C BSA 1 BSA 1 IgG 1 mg/mL

0.25 mg/mL mg/mL mg/mL
Protein NaCL Protein NaCL Protein NaCL Protein NaCL

Recovery Removal Recovery Removal Recovery Removal Recovery Removal
Spin 1 100% 99% 97% 99% 97% 99% 90% 98%
Spin 2 96% 100% 92% 100% 93% 100% 87% 100%
Four Vivaspin® 20 devices of each brought up to 20 mL with ultrapure

MWCO were tested with 20 mL sam- water from an Arium® system (Sartorius).
ples. Each sample contained 500 mM OD readings were taken at 410 nm for
NaCl. To perform diafiltration, devices Cytochrome C or 280 nm for BSA and
were centrifuged at 4,000 g for 45 min IgG samples. Salt concentrations were
(5 kDa MWCO) or 30 min (>5 kDa measured using a Qcond 2200
MWCOs). After the first and second conductivity measuring instrument.
spins, the retentate samples were
Vivaspin® 6
MWCO 5 kDa 30 kDa 50 kDa 100 kDa
Cytochrome C BSA 1 BSA 1 IgG 1 mg/mL

0.25 mg/mL mg/mL mg/mL
Protein NaCL Protein NaCL Protein NaCL Protein NaCL

Recovery Removal Recovery Removal Recovery Removal Recovery Removal
Spin 1 98% 99% 92% 99% 93% 99% 92% 98%
Spin 2 85% 100% 86% 100% 83% 100% 89% 100%
Four Vivaspin® 6 devices of each were brought up to 6 mL with

MWCO were tested with 6 mL ultrapure water from an Arium® system
samples. Each sample contained 500 (Sartorius). OD readings were taken at
mM NaCl. To perform diafiltration, 410 nm for Cytochrome C or 280 nm
devices were centrifuged at 4,000 g for BSA and IgG samples. Salt
for 45 min (5 kDa MWCO) or 30 min concentrations were measured using a
(>5 kDa MWCOs). After the first and Qcond 2200 conductivity measuring
second spins, the retentate samples instrument.
Conclusions r emoval to 99% with >92% recovery of

As the results show, the efficient de- the target protein. Diafiltration using
sign of Vivaspin® devices allowed >95% ultrafiltration devices such as Vivaspin®
of the salt to be removed during the 6 and 20 represents a faster and more
first centrifugation step. Only one efficient solution to desalting and
subsequent centrifugation step was buffer exchange, than conventional
needed to increase the typical salt techniques such as dialysis.
74 Application Notes 1. Desalting and Buffer Exchange with Vivaspin®

2. Treatment of Vivaspin® Concentrators for Improved
Recovery of Low-Concentrated Protein Samples
Introduction Table 1: Passivation Solutions
With appropriate device size and
membrane cut-off selected, Vivaspin® Type Concentration
products will typically yield recoveries Powdered milk 1% in Arium® water
for the concentrated sample > 90%
BSA 1% in PBS
when the starting sample contains
over 0.1 mg/mL protein of interest. Tween 20 5% in Arium® water
Depending on sample characteristics SDS 5% in Arium® water
relative to the membrane type used, Triton X-100 5% in Arium® water
solute (protein) adsorption on the
PEG 3000 5% in Arium® water
membrane surface is typically very
low (2 – 10 μg/cm²) and in practice
not detectable. Passivation procedure for Vivaspin®
ultrafiltration concentrators
This can increase to 20 – 100 μg/cm²
when the filtrate is of interest and the A) Passivation procedure
sample must pass through the whole 1. Wash the concentrators once by
internal structure of the membrane. filling with Arium® water and spin
Whilst the relative adsorption to the the liquid through according to the
plastic of the sample container will be respective protocol.
proportionately less important than on 2. Remove residual water thoroughly
the membrane, due to the higher total by pipetting.
surface area, this can be also be a Caution: Take care not to damage
source of yield loss. Typically, a higher the membrane with the pipette tip.
cut-off membrane will bind more than 3. Fill concentrators with the blocking
a low molecular weight alternative. solution of choice as given in Table 1.
4. Incubate the filled concentrators at
Whenever possible, the smallest room temperature for at least 2
MWCO and device size applicable hours (overnight is also possible
should be chosen. Swinging bucket except for Triton X-100 which is not
rotors are preferred to fixed angle recommended for overnight
rotors. This reduces the surface area of incubation).
the concentrator that will be exposed 5. Pour out the blocking solution.
to the solution during centrifugation. 6. Rinse the device 3 – 4 × very
thoroughly with Arium® water and
An important factor not to be finally spin through.
neglected is the thorough recovery of 7. The “passivated” devices are now
the retentate. Make sure to carefully ready for use. We recommend
remove all traces of solution from the comparing different passivation
sample container and, if feasible, rinse reagents with an untreated device.
the device after recovering the sample
with one or more drops of buffer and Note
then recover again. It is necessary to rinse the device
thoroughly before each washspin
The intention of the following “passiva- to ensure that traces of passivation
tion” procedure is to improve recovery compound are removed from the
of protein samples in the nano- to deadstop. Use the device immediately
microgram concentration range by for protein concentration or store it at
pretreating the device (membrane & 4°C filled with Arium® water, to prevent
plastic). For this purpose a range of the membrane from drying.
solutions are suggested in Table 1.
Application Note 2. Passivation of Vivaspin® Concentrators 75

B) Evaluation of passivation effects Results and discussion
(exemplary with BSA) As an example, the effect of milk
1. Prepare a 10 μg/mL BSA stock powder was analysed. It could be
solution e.g. by diluting 90 μL of the shown (Figure 1) that the protein
4 mg/mL stock solution in 36 ml 0.1 recovery of a 10 μg/mL BSA solution
M sodium borate pH 9.3. Mix well. could be increased from around 70 to
2. Fill Vivaspin® 2 devices with 2 ml 90%. If milk powder is not interfering
of this 10 μg/mL BSA solution and with sample purity and quality, it is a
close with cap provided. good starting point to improve
3. Spin the device in a swing-out rotor recovery of diluted sample solutions.
at 4,000 × g until the volume is to
app. 100 μL. Protein recovery (10 μg/mL BSA) with
4. R ecover the concentrate and make Vivaspin® PES 10 kDa after passivation
back up to 2 mL with 0.1 M sodium In another example, detergents were
borate pH 9.3 analysed with only 250 and 500 ng
5. Determine recovered protein BSA (Figure 2) BSA recovery declined
concentrations e.g. according to to 50 – 30% in untreated devices as
Bradford or BCA assays. the protein concentration was
reduced. Significant improvement to
60 – 90% recovery could be
demonstrated when using the
passivation strategy. Often, Triton
X-100 seemed to work though the
optimal reagent has to be selected for
the respective protein and its
hydrophilic | -phobic characteristics.
76 Application Note 2. Passivation of Vivaspin® Concentrators

Recovery comparison of passivation with milk powder
100
80
60
40
20
0
milk powder untreated
Figure 1: Protein recovery (10 µg/mL BSA) with Vivaspin® PES 10 kDa after passivation
Recovery comparison of passivation with common buffer solutions
PEG Triton X-100
100 Tween untreated
80
60
40
20
0
250 ng 500 ng
Figure 2: Protein recovery (250 and 500 ng BSA) with Vivaspin® 2 PES 10 kDa after passivation
Summary device will reduce losses on the plastic

Passivation is an appropriate method surface. One very important thing to
to achieve increasing sample recovery remember is that the blocking agent is
when using very dilute samples. In ad- potentially introduced into the sample.
dition to skimmed milk, other proteins It should be assured that this will not
(BSA), detergents and compounds are interfere with downstream analysis.
possible. However, it should be noted
that this is a general procedure, not For example, proteins must not be
specific for any particular application. used for passivation if a pure protein
Depending on the hydrophilic | is intended to be concentrated for
-phobic character of the protein x-ray crystallography, as even the
non-specific binding may be more or smallest traces would interfere with
less of a problem and the suggested the diffraction pattern. Other subse-
passivation solutions may lead to dif- quent analyses methods include
ferent results. Even with the Hydrosart activity testing, gel electrophoresis
membrane, which is recommended or labelling are less problematic.
for dilute samples, passivation of the
Application Note 2. Passivation of Vivaspin® Concentrators 77

3. Scouting Protein Purification Conditions Using
Vivapure® Centrifugal Ion Exchange Membrane Absorbers
Introduction The results from this experiment
For separation and purification of provided the optimal binding pH and
proteins from biological samples, the best ion exchange chemistry for
different characteristics of the target the purification of SH2 domain.
protein e.g. its size, charge,
hydrophobicity or specifically In a second step, the best elution
engineered tags, are exploited. method was evaluated by applying
increasing salt concentrations to
With ion exchange chromatography, columns which were shown to bind
separation is achieved on the basis of the target protein in step one, leading
charge differences between to a complete purification protocol in
biomolecules. This makes it a versatile less than one hour.
method often used for pre-
fractionation or purification of a target Materials and Methods
protein from crude protein mixtures. Buffers tested to determine the
To optimize the purification procedure optimum pH and salt concentration
for an individual target, several binding for binding and elution in ion
and elution conditions have to be exchange purification of SH2 domain
tested on cation and anion exchange
matrices. Buffer A: 25 mM Citrate, pH 4
Buffer B: 25 mM Potassium phosphate, pH 6

In contrast to traditional column
Buffer C: 25 mM HEPES, pH 8
chromatography methods, Vivapure®
IEX centrifugal columns allow scouting Buffer D: 25 mM Sodium bicarbonate, pH 10
of several chromatography conditions Buffer E: 25 mM Citrate, pH 4, supplemented
in parallel, leading quickly to different with 1 M NaCl.
fractions which can be further analyzed Buffer F: 25 mM Potassium phosphate, pH 6,
for enriched or even already purified supplemented with 0.2 M, 0.4 mM,
target protein. 0.6 mM, 0.8 mM and 1 M NaCl,
respectively.
Here, we demonstrate the performance Buffer G: 25 mM HEPES, pH 8, supplemented

with 1 M NaCl
of Vivapure® IEX Mini spin columns for
evaluation of optimal purification Buffer H: 25 mM Sodium bicarbonate, pH 10,
supplemented with 1 M NaCl
conditions of cloned SH2 domains
from an E. coli lysate in a two step
procedure. This protocol can generally
be employed for identifying a
purification method based on ion
exchange chromatography for a given
target protein, as it is fast and only uses
small amounts of the sample.
In the first step of this study, binding

conditions were evaluated by loading
the sample on Vivapure® Q and S
columns at various pH values, eluting
bound proteins with a high salt
concentration buffer and analyzing all
fractions for the target protein.
78 Application Note 3. Scouting Protein Purification Conditions

Scouting Binding Conditions Afterwards, Vivapure® Mini spin
300 mL LB media was inoculated columns were reloaded with 400 μL
with 4 mL of an overnight culture and sample and spun again for 5 min at
incubated at 37°C, shaking at 150 rpm 2,000 g. Loosely bound proteins were
until an OD600 of 1.0 was reached. washed away with the application of
IPTG was added to a final 400 μL of the respective binding
concentration of 1 mM and the culture buffer to each of the columns and
incubated for a further 4 h with shaking spinning for 5 min at 2,000 g. Flow-
at 150 rpm. Cells were harvested by through and wash fractions were
centrifugation at 4,000 g for 30 min at collected for subsequent detection of
4°C. The pellet was resuspended in 35 the target protein.
mL PBS (150 mM KPi, pH 7.3) and cells
were lyzed by addition of lysozyme to a 200 μL of elution buffer E, F, G or H,
final concentration of 0.1 mg/mL and were applied to the washed columns
incubation for 1 h at 37°C. Insoluble and spun for 3 min at 2,000 g. Eluates
particles and cell debris were removed were saved for subsequent analysis.
by centrifugation at 10,000 g for
30 min at 4°C. 4 μL of flow-through, wash, and eluate
fractions from each column were
4 × 200 μL aliquots of the cell lysate analyzed by reducing SDS-PAGE
were diluted with 1.8 mL binding buffer followed by silver staining.
A to D, to adjust each sample to the
respective pH being tested. To avoid Optimizing Elution Conditions
clogging of the membranes in the Taking account of the results of the
Vivapure® Mini spin columns, samples first experiment (Scouting Binding
were clarified by passage through Conditions) 200 μL cell lysate was
0.45 μm CA Minisart NML syringe diluted with 1.8 mL binding buffer B
filters (Sartorius). (25 mM KPi, pH 6). To avoid clogging
of the membrane in the Vivapure® Mini
4 × Q and 4 × S Vivapure® Mini spin spin column, the pH adjusted sample
columns were labeled 4, 6, 8 and 10, was clarified by passage through a
corresponding to the pH of the buffer 0.45 μm CA Minisart NML syringe
to be used. To each spin column, filter (Sartorius).
400 μL of the corresponding binding
buffer was added and spun for 5 400 μL binding buffer B was applied
minutes at 2,000 g (45° fixed angle to one Vivapure® S Mini spin column
rotor). and spun for 5 minutes at 2,000 g.
400 μL of the clarified samples 400 μL of the clarified sample was

adjusted to pH 4, 6, 8 or 10 were applied to the equilibrated Vivapure® S
applied to each of the correspondingly column and spun for 5 min at 2,000 g.
equilibrated Vivapure® Q and S spin Afterwards, the Vivapure® S Mini spin
columns. Columns were spun for 5 min column was reloaded with 400 μL
at 2,000 g. sample and spun again for 5 min at
2,000 g.
Application Note 3. Scouting Protein Purification Conditions 79

Loosely bound proteins were washed Results
away by application of 400 μL binding Dilution of the E. coli lysate with
buffer to the column and spinning for binding buffer A (25 mM Citrate, pH 4)
5 min at 2,000 g. Flow-through and lead to complete precipitation of
wash fractions were saved sample proteins. Thus, pH 4 could not
for analysis. be tested in this experiment. As can be
seen on the SDS gel in (Figure 1), the
To elute the target protein, 100 μL target protein was present in the
elution buffer F, supplemented with eluates from Vivapure® Q Mini spin
0.2 M NaCl was applied to the columns at all pH values tested,
Vivapure® S Mini spin column and together with most of the E. coli
spun for 3 min at 2,000 g. The eluate proteins (Lanes Q “e”). In contrast,
was collected. For the next elution using the Vivapure® S Mini spin
step, 100 μL of elution buffer F, column, at all pH values tested, most E.
supplemented with 0.4 M NaCl was coli proteins did not bind to the
applied and again spun for 3 min at membrane and were found in the
2,000 g. Elution was continued with flow-through (Lane S “f”), thus
0.2 M NaCl increments until a final resulting in purer target protein in all
salt concentration of 1 M was reached, eluate fractions (Lane S “e”).
saving the eluates from each step.
Differences could be detected in
4 μL of flow-through, wash, and eluate the binding efficiency of the target
fractions from each column were protein. At pH 8, traces of the target
analyzed by reducing SDS-PAGE protein were already found in the flow-
followed by silver staining. through, with slightly higher amounts
at pH 10 (Lane S “e”). At pH 6, the most
efficient binding of the target protein
to the S membrane was observed.
The purification conditions

determined for Vivapure® S with
potassium phosphate buffer (pH 6)
were further optimized to determine
the ideal salt concentration for SH2
domain elution. The target protein
started to elute with 200 mM NaCl,
however the main fraction eluted with
400 mM NaCl. Traces of the target
protein were also found in the next
elution step with 600 mM NaCl, but
this might be due to the low elution
volume.
80 Application Note 3. Scouting Protein Purification Conditions

Figure 1
pH = 6 pH = 8 pH = 10
66 kDa
45 kDa
Target
protein
31 kDa
22 kDa
Sample Sample Volume (μL) Volume Loaded Onto Gel (μL)
M = Broad range marker
s = Sample before application 800 4
f = Flow-through 800 4
w = Wash fraction 400 4
e = Elution with 1 M NaCl 200 4
Note: Scouting for optimal binding conditions of a SH2 domain expressed in E. coli. 12% reducing
SDS gel, silver stained, shows the sample before purification (s), flow-through (f), wash (w) and
eluate (e) fractions (1 M NaCl) from Vivapure® Q and S Mini spin columns, at the various pH values
tested.
Application Note 3. Scouting Protein Purification Conditions 81

Figure 2
66 kDa
45 kDa
Target
protein
31 kDa
22 kDa
Sample Process Volume (µL) Volume Loaded Onto Gel (µL)
M = Broad range marker
s = Sample before application 800 16
f = Flow-through 800 16
w = Wash fraction 400 16
e1 = 25 mM KPi, pH 6, 200 mM NaCl 100 8
e2 = 25 mM KPi, pH 6, 400 mM NaCl 100 8
e3 = 25 mM KPi, pH 6, 600 mM NaCl 100 8
e4 = 25 mM KPi, pH 6, 800 mM NaCl 100 8
e5 = 25 mM KPi, pH 6, 1 M NaCl 100 8
Note: Optimizing elution conditions for a SH2 domain expressed in E. coli, using Vivapure® S Mini
spin column at pH 6. 12% reducing SDS gel, silver stained, shows the sample before purification (s),
flow through (f), wash (w) and eluate (e1-5) fractions.
-
Conclusion The results obtained in this experiment
A two-step procedure was used to can be used to various ends, e.g:
--
rapidly scout optimal purification Polishing a specific protein after
conditions for a target protein (a SH2 purification with another chromato-
domain from E. coli lysate) with ion graphic technique
exchange chromatography. In the first Quickly establishing a FPLC method
step, the most suitable ion exchanger for a new protein
and buffer pH for binding the target Identification of the optimal purifica-
protein was verified. In the second step, tion method prior to scale up with
the elution condition was optimized, Vivapure® IEX Maxi spin columns.
building on the results gained in step
one. With the scouting procedure For these purposes Vivapure® IEX Mini
described here, it was possible to and Maxi spin columns and Sartobind®
quickly and conveniently purify the membrane adsorber units with FPLC
target protein to homogeneity. connectors are available.
82 Application Notes 3. Scouting Protein Purification Conditions

4. Concentration and Purification of Viruses by Using
Ultrafiltration, Incl. Coronavirus – A Short Review
Introduction This short review highlights methods
Evolutionary, viruses developed various for the purification of various
mechanisms to interact and manipulate mammalian viruses for basic medical
the genetic material of their target cells. research. Also, the concentration of
Based on this, m odern molecular pathogenic viruses from water and
biology utilizes viruses in a constantly food samples and the purification of
growing number of applications.¹ marine bacteriophages (virioplankton)
They range from controlled genetic are highlighted. It will also give
transfection of cells to a variety of guidance for the selection of an ideal
different basic studies in medical performing device with the optimum
science.² In medical studies the molecular weight cut-off (MWCO) for
strategic focus is on recombinant the user specified ultrafiltration
vaccines and on the development of process.
potential vectors for gene therapy.³,⁴
Concentration of mammalian viruses
Besides the great relevance of viruses in medical research
for medical applications, the In medical research viruses and VLPs
assessment of virus type and content are of major interest, particularly for
is important for the risk assessment of investigations on infectious viral
food and drinking water.⁵ Also, the diseases and for the development of
classification of virus content is often vaccines or antiviral drugs. Moreover,
of high relevance for the quality certain VLPs can manipulate genetic
control of aquatic biotopes.⁶ material in a directed manner and are
used broadly in the development of
During the preparation, handling, or genetic therapy approaches.
analysis of viruses orvirus-like particles Additionally, viral vectors are well
(VLPs), a concentration and | or established as a transfection method
purification step is frequently required.⁵ for gene transfer to cell lines e. g. to
Typical viruses have a size within the manipulate mammalian cells in vivo
range of about 20 nm up to several and in vitro.
hundred nanometers.⁷ Therefore they
are ideally suited for the retention on An overview of thematically linked
ultrafiltration membrane systems and publications using Sartorius
such ultrafilters are widely used in basic ultrafiltration devices for the
virus research. The specifications of purification and concentration of
such ultrafiltration devices depend on viruses and VLPs in the medical
the particular type of virus and the context is given in Table 1. Among
purpose of the subsequent application. other applications, Vivaspin® devices
were employed for the concentration
of adeno-associated virus (AAV) and
lentiviral vectors after purification via
ion exchange chromatography,⁸–¹⁰ on
blood sera to prepare blank samples
from hepatitis C virus (HCV)-positive
blood sera,¹¹ for the development of a
vaccine against human
immunodeficiency virus (HIV) and of
an antiviral drug against C hikungunya
virus.¹²,¹³
Application Notes 4. Concentration and Purification of Viruses 83

Table 1: Summarized examples of applications using Vivaspin® and Vivaflow®
for viruses in medical research
Goal of Research Purpose of Filtration Sartorius Subsequent Step Ref.

(Type of virus, (Buffer System) Ultrafiltration
Host Organism) Device (MWCO)
Gene therapy Diafiltration Vivaflow® Storage, chromatography 14

(Adenovirus type 5, (20 mM Tris saline (100 kDa) on Sartobind® STIC
VLP, human) buffer) membrane absorber
(FPLC)
Reduction of Removal of HCV Vivaspin® Preparation of negative 11

HCV-induced from human blood (30 kDa) control (from positive
fibrosis (Hepatitis C serum (Blood serum) sample) for immunofluores-
Virus; human) cence assay, fibrosis
induction assays
Development of a Removal of protein Vivaspin® 20 Virus inactivation 12

viral entry inhibitor for fraction from virus (1,000 kDa)
HIV (HIV, human) (PBS)
Gene therapy for Concentration and Vivaspin® 20 Titer, ELISA, cell binding 8
cancer treatment purification after (1,000 kDa) assay, apoptosis | cell cycle
(adeno-associated expression, Buffer assay
virus; rAAV-2, human) exchange after
His tag (FreeStyle 293
Expression Medium
(Gibco), serum-free)
System for controlled Concentration of Vivaspin® 20 Transduction of mice 9

gene expression in eluate after anion (100 kDa) neurons
mice brain (Adeno- exchange chromatog-
associated virus, mice) raphy (elution buffer)
Efficient gene transfer Concentration after Vivaspin® Quantification via real- 10

into the CNS ion exchange (100 kDa) time PCR and end-point
(Lentivirus, human) chromatography dilution. Transduction of
(PBS) murine neuronal and glial
cells in vivo
Identification of Concentration Vivaspin® 20 Quantification by TCID₅₀ 13

effective chikungunya (100 kDa)
antiviral drugs
(Chikungunya-Virus,
human)
Gene therapy of Concentration Vivaspin® 4 Titer determination 15

achromatopsia in (Anion exchange (10 kDa) by dot-blot analysis,
mice (Recombinant chromatography subretinal injections
adeno-associated elution buffer)
virus, human virus
used in mice)
84 Application Notes 4. Concentration and Purification of Viruses

Concentration of viruses from independent of the chemical
drinking water and food samples properties and the structure of the
The guidelines for drinking-water virus.¹⁷ Thus ultrafiltration is very well
quality by the world health suited to isolate and concentrate virus
organization describe safety plans to particles from water samples and is a
reduce potential risks from various valuable aid during the assessment of
virus infections.¹⁶ It states that, due to water quality. Most of the viruses
the increased resistance of viruses to which are found in water and also food
disinfection methods, an absence of samples are of fecal origin. Screening
bacterial contamination after for these viruses is crucial to prevent
disinfection cannot be used as a infections. The most frequent ones are
reliable indicator of the presence | hepatitis A, hepatitis E and norovirus.¹⁸
absence of pathogenic viral species in Ultrafiltration has been described as
drinking water supplies. Considering the most appropriate method for the
this, ultrafiltration can play a vital role recovery of hepatitis A virus from
in detecting such viral contaminations vegetables and other food items.¹⁹
for the research on drinking water Detection of infectious viruses is
quality and food safety. mainly done by propagation in cell
culture (plaque assay) or the detection
For an ultrafiltration step, the water of the viral genomes by molecular
sample does not have to be pre- amplification techniques such as
conditioned and its efficacy in quantitative reverse transcriptase
concentrating the virus is virtually polymerase chain reaction (RT-PCR).²⁰
Table 2: Summarized examples of ultrafiltration applications using Vivaspin®

and Vivaflow® for viruses from drinking water and food samples
Goal of Research Purpose of Filtration Sartorius Ultra- Subsequent Step Ref.

(Type of virus, (Buffer System) filtration Device
Host Organism) (MWCO)
Method for the Concentration (PBS Vivaspin® RNA extraction for 22

detection of norovirus processed (5 kDa) real-time RT-PCR
genogroup I food samples)
(Norovirus, human)
Analysis of viral con- Concentration of Vivaflow® 200 Qualitative analysis 21

tent in groundwater drinking water sample (10 kDa) (enterovirus) by
(A set of pathogenic (Drinking water) RT-nested PCR and
viruses, potentially microtiter neutralization
human) test
Comparative Analysis Concentration Vivaspin® 20 RNA extraction for 19

of Viral Concentration (0.25 M threonine, (100 kDa) real-time RT-PCR
Methods (Hepatitis A 0.3 M NaCl, pH 9.5)
virus, human)
Analysis of regional Concentration Vivaspin® 2 Nucleic acid extraction 23

outbreak of gastro- (50 mmol/L glycine
enteritis due to drink- buffer, 1% beef
ing water contamina- extract)
tion (Norovirus,
Astrovirus, Rotavirus,
Enterovirus, Hepatitis
A virus; human)

Concentration of viruses and chemical and structural properties
bacteriophages from marine of the viruses. Thus, it finds wide use
biological samples for the analysis of aquatic viruses.
In marine biology, the concentration For instance, Schroeder et al. (ref. 26)
and subsequent analysis of marine were able to determine the diversity
bacteriophages (virioplankton) is of and monitor population dynamics of
major interest. They outnumber the viruses that infect Emiliania huxleyi, a
bacterioplankton (their host globally important form of
organisms) by an order of magnitude photosynthetic plankton. In this study
and thus have an important influence a reusable Vivaflow® 50 unit equipped
on the whole marine biosphere.²⁴ with a polyethersulfone (PES)
membrane with MWCO of 50 kDa was
As described by Wyn-Jones & used to concentrate viruses in sea
Sellwood (ref. 17) ultrafiltration can water s amples prior to storage and
be used to concentrate virus particles analysis. For further examples of virus
in water samples without any prior concentration from marine biological
pretreatment of the sample and it is samples see table 3.
also practically independent from the
Table 3: Summarized examples of ultrafiltration applications using Sartorius

Vivaflow® and Vivaspin® for samples from marine biology
Goal of Research Purpose of Filtration Sartorius Ultra- Subsequent Step Ref.

(Type of virus, (Buffer System) filtration Device
Host Organism) (MWCO)
Assessment of 0.2 μm filtration for Vivaflow® 200 Subsequent analysis 25

virioplankton diversity clarification, filtrate (0.2 μm and by DNA separation
(Virioplankton, Plankton) subjected to 3 kDa 30 kDa) on Agarose gel
filter for concentration
(Sea water)
Classification of virus Vivaflow® 200: harvest Vivaflow® 200, Classification of 28

(MpRNAV-01B, and concentration Vivaspin® new virus: genome,
Micromonas pusilla) of whole cell lysate; (30 kDa) proteins, stability,
Vivaspin®: washing etc.
(removal of CsCl)
Assessment of genetic After 0.45 μm filtration, Vivaflow® 50 PCR and Denaturing 26

diversity in virioplankton concentration 1 L to (50 kDa) gradient gel
(Emiliania huxleyi Bloom 20 mL (Sea water) electrophoresis
virus, Eukaryotic
phytoplankton - alga)
Investigation of gene Concentration Vivaflow® 50 CsCl-gradient 27

expression during from 5 L to 20 mL (50 kDa)
infection (Emiliania (f/2 medium)
huxleyi virus strain
86, Eukaryotic
phytoplankton - alga)
Study on host genome Clarification with 0.2 μm Vivaflow® 200 CsCl gradients, 29
integration (virophage filter and concentration (0.2 μm and electron microscopy
mavirus, Cafeteria with 100 kDa filter 100 kDa)
roenbergensis) (Cafeteria roenbergen-
sis, f/2 medium)

Concentration of Coronavirus A key component to the infection
for general research and protein cycle is the coronavirus spike (S)
research (spike protein) protein, that mediates entry into host
Coronaviruses are spherical, enveloped, cells, through both attachment and
RNA based viruses that are typically membrane fusion. As such, it is a
80 – 120 nm in diameter, but in many primary target for the development of
cases have a diameter outside of this novel antiviral drugs and vaccines.
range. Coronavirus genomes are the
largest of all RNA viruses which offers The concentration and purification of
a relatively large area of study. both the virons and the spike proteins
Correlatingly the potential for future from cell culture and supernatants is
mutations in this large genome may often a key requirement to isolate the
lead to future human diseases that respective target, prior to structural,
may evolve into epidemics and functional analysis and binding assays,
pandemics, such as the previous etc.
Middle East Respiratory Syndrome
(MERS-CoV), and Severe Acute Table 4 highlights several applications
Respiratory Syndrome 1 (SARS-CoV-1) where Vivaspin® centrifugal
and 2 (SARS-CoV-2). Hence further concentrators, or Vivaflow® tangential
research into the replication, flow f iltration cassettes have been
transmission, genome and structure used for the concentration or
will continue with greater investment Coronavirus proteins, including the
of time and funding in the years to spike protein. References are also
come. provided to direct readers for detailed
reading.
Table 5 provides examples of

concentration of intact virons, or
Coronavirus virus like particles (VLPs),
with the same devices.

Vivaflow® and Vivaspin® for coronavirus protein samples.

(Type of virus, Host (Buffer System) Ultrafiltration
Organism) Device
(MWCO)
Neutralization of a Buffer exchange of a Vivaspin® 20, Protein concentra- 30

SARS-CoV-2 antibody to SARS-CoV-2 RBD PES (10 kDa) tion by UV/Vis and
a functionally conserved protein binding affinity
receptor binding domain by Streptavidin BLI
(RBD) on the trimeric (Sartorius Octet)
spike (S) protein
Investigation of Concentration of Vivaspin® 20, Purification by SEC 31

neutralising antibody SpyTag-RBD protein PES (10 kDa)
response on a SARS- construct
CoV-2 spike glycoprotein
RBD-SpyVLP (virus-like
particle) platform
Investigation of exosome Concentration of Vivaspin®, PES Western blot 32

based vaccines contain- solubilized spike protein (10 kDa) analysis
ing coronavirus spike (S) in supernatant
protein, for SARS-CoV-1
Analyze of the ability to Concentration of Vivaspin®, PES Western blot 33

redirect the functionality cellular receptor protein analysis
of the Mouse Hepatitis constructs
coronavirus spike (S) pro-
tein to infect
human cancer cells
Structure determination Concentration of Vivaspin®, PES Crystalization 34

of coronavirus SARS- coronavirus nsp1 during screening
CoV-1 non-structural purification process
protein 1 (nsp1)
Structure determination Concentration of Vivaspin®, PES Crystalization 35

of the ADRP domain coronavirus nsp3 during (10 kDa) screening
of Feline Coronavirus purification process
(FCoV) non-structural
protein 3 (nsp3)
Investigation into the role Concentration of VLPSs Vivaspin®, PES Cell-cell fusion 36
of three transmembrane from HEK 293T cell assay
proteases in the activa- culture supernatant
tion of SARS-CoV-1 spike
(S) protein
Cryo-electron micros Concentration of Vivaflow®, PES Affinity purification 37

copy of Human Corona recombinant HCoV- (10 kDa)
virus HCoV-NL63 spike NL63 viruses from
glycoprotein trimer that clarified Drosophila S2
is a potetial target for cell culture supernatant
neutralizing antibodies
during infection

Vivaspin® for coronavirus viron and VLP samples

Organism) Device
(MWCO)
Characterisation of Concentration of Vivaspin®, PES Quantification 38

phenotypic changes in MERS-CoV virus isolates (100 kDa) using plaque titra-
virus isolates, such as tion Viral RNA
MERS-CoV, that could sequencing analysis
relate to pandemic
potential
Investigation of antiviral Concentration of MERS- Vivaspin® 20, Limiting dilution 39

potential of Echinacea CoV and SARS-CoV virus PES assay (TCID₅₀)
purpurea (Echinaforce®) dilutions
against human
coronaviruses; SARS-
CoV and MERS-CoV
Investigation into Concentration and Vivaspin® 500, Inoculation 40

inactivation of separation of deactivat- PES onto Vero-E6
SARS-CoV-2 through ed SARS-CoV-2 from monolayer
heating and chemical lysis buffer
protocols
Investigation of viral and Concentration of SARS- Vivaspin®, PES Western blot 41,
cellular determinants CoV and hCoV-EMC analysis 42
governing hCoV-EMC virus like particles (VLPs)
entry into host cells

Concentration and capture of virons The severity of this pandemic is driving
and | or viral RNA in wastewater increased research and funding in all
In humans and birds Coronaviruses associated areas. Once area is on the
may inflict mild to fatal respiratory tract tracking and epidemiological studies
infections, but in other animal groups of SARS-CoV-2 infections. One area
a range of other diseases may also of focus is in the use of regional
occur, such as hepatitis and wastewater systems, where the
neurological illness⁴². SARS-CoV-2 is compartmentalisation of these
the most recent among a string of systems offers distinct tracking in real
Coronavirus epidemics, which early time, without the lag for symptom
indications suggest that due to its high appearance and clinical diagnosis⁴³. In
infectivity, rates of asymptomatic addition, the data collected can be
infection, significant incubation time, used as a supplemental and low-cost
our relatively limited knowledge of surveillance indicator on the
transmission dynamics and overall lack circulation of the virus in a community
of g
lobal pandemic preparation, has without the need to screen individuals.
evolved into a true global pandemic Further, it c
ontributes to the tracking
and has caused significant impact on of infection prevalence, by adding
global health, society and economy. another epidemic indicator⁴⁴.
RT-PCR is the standard method to

test for SARS-CoV-2, but samples
typically require concentration and
removal of non-Coronavirus material
prior to testing to ensure optimal
results. Ultrafiltration is a successful
method for this⁴³, and some examples
have been given in Table 6.

Vivaflow® and Vivaspin® for virus and viral RNA in wastewater samples

Organism) Device (MWCO)
Measurement of SARS- Concentration of viral Vivaspin®, PES Viral RNA extraction 43,
CoV-2 RNA in sewage RNA (50 kDa) and purification RT- 44,
qPCR quantification 45
Benchmarking virus Concentration of viral Vivaspin®100, Viral RNA extraction 46

concentration methods RNA PES (10 kDa) and purification RT-
for quantification of SARS- qPCR quantification
CoV-2 in raw wastewater
Evaluation of two Concentration of viral Vivaspin® Viral RNA extraction 47

methods to concentrate RNA from 40 ml (total) (10 kDa) and RT-qPCR and
SARS-CoV-2 from to 700-1000 µl ddPCR
untreated wastewater quantification
Virus detection in full scale Concentration of viral Vivaflow® 50, PEG precipitation 48
membrane bioreactor particles in effluent PES Viral
(MBR) plant by virus RNA quantification
concentration monitoring,
inc. Norovirus, Sapovirus
and Rotavirus
Evaluation of membrane Concentration of Vivaflow® 50, Nucleic acid 49

bioreactor wastewater effluent from 1 L to 40 PES extraction
virus removal, inc. mL RT-PCR
Norovirus, Sapovirus, quantification
Adenovirus
Evaluation of membrane Concentration of Vivaflow® 50, Nucleic acid 50

bioreactor wastewater viruses in effluent PES extraction
Norovirus removal RT-PCR
quantification
Evaluation of the Concentration of Vivaflow® 50, Nucleic acid 51

association between viruses in effluent PES extraction
number of hepatitis E RT-qPCR
cases in the community quantification
and concentration in local
sewage

Conclusion Abbreviations
The purification of virus by ultrafiltration AAV Adeno-associated virus
is virtually independent of the chemical CNS Central nervous system
properties and the structure of the virus DNA Deoxyribonucleic acid
particles. As viruses have a size within CoV Coronavirus
the range of about 20 nm up to several ELISA Enzyme-linked
hundred nanometers, they are typically immunosorbent assay
several orders of magnitude bigger FPLC Fast protein liquid
than even the largest protein chromatography
complexes.⁷ Therefore, most viruses are fCoV Feline Coronavirus
unfailingly retained on membranes with hCoV Human Coronavirus
MWCOs up to 1,000 kDa. The exact HCV Hepatitis C virus
specifications of the ideal ultrafiltration HIV Human immunodeficiency
membranes depend on the purpose of virus
the subsequent application. kDa Kilodalton (1,000 g per
mole)
Ultrafiltration for the concentration of M Molarity (mole per litre)
Coronavirus species plays and MERS Middle east respiratory
important role in a range of workflows. syndrome
Perhaps due to the size distribution of mol Mole
viruses and VLPs, the exact MWCO MWCO Molecular weight cut-off
used is not standard across each study. nsp Nonstructural protein
Although typically, for 80 – 120 nm PBS Phosphate buffered saline
particles the 100 kDa MWCO would PCR Polymerase chain reaction
provide the optimal balance between PEG Polyethylene Glycol
recovery, removal of interfering PES Polyethersulfone
substances, speed and shear stresses. RNA Ribonucleic acid
Whereas for the recovery of RNA SARS Severe acute respiratory
material, lower MWCOs (10 – 50 kDa) syndrome
are recommended to capture a greater RBD Receptor binding domain
range of RNA chain lengths. However, BLI Bio-Layer Interferometry
until further standardization is c
onfirmed RT-PCR Reverse transcriptase-
for each application, it is prudent to test polymerase chain reaction
specific devices before implementing ddPCR Droplet digital polymerase
into procedures. chain reaction
TCIDP50 50% Tissue culture infective
During the preparation of viral vectors dose
for medical studies, a buffer exchange VLP Virus-like particle
after column purification can be
performed with various MWCOs of all
sizes.⁸,⁹,¹⁰,¹⁵ To separate virus particles
from small proteins, a 1,000 kDa cut
off has been shown to work.¹² For the
complete removal of HCV from blood
serum a 30 kDa MWCO has been
utilized.¹¹ When the assessment of
whole virus content is crucial (e.g. food,
drinking water or marine water samples)
smaller MWCOs (5 – 100 kDa) are
used to ensure full recovery of virus
particles.¹⁹,²¹,²²,²⁵-²⁹

References 16. Guidelines for drinking-water quality - 4th
1. Vannucci, L., Lai, M., Chiuppesi, F., ed. World Health Organization 2011.
Ceccherini-nelli, L. & Pistello, M. Viral vectors 17. Wyn-Jones, a P. & Sellwood, J. Enteric viruses
: a look back and ahead on gene transfer in the aquatic environment. J. Appl.
technology. New Microb. 36, 1–22 (2013). Microbiol. 91, 945–962 (2001).
2. Luo, D. & Saltzman, W. M. Synthetic DNA 18. Botzenhart, K. Viren im Trinkwasser.
delivery systems. Nat. Biotechnol. 8, 33–37 Bundesgesundheitsblatt - Gesundheits-
(2000). forsch. - Gesundheitsschutz 50, 296–301
3. Ura, T., Okuda, K. & Shimada, M. Developments (2007).
in Viral Vector-Based Vaccines. Vaccines 2, 19. Lee, K. B., Lee, H., Ha, S. D., Cheon, D. S. &
624–41 (2014). Choi, C. Comparative analysis of viral
4. Mingozzi, F. & High, K. A. Therapeutic in vivo concentration methods for detecting the
gene transfer for genetic disease using AAV: HAV genome using real-time RT-PCR am-
progress and challenges. Nat Rev Genet 12, plification. Food Env. Virol. 4, 68–72 (2012).
341–355 (2011). 20. Bosch, A. et al. Analytical Methods for Virus
5. Soule, H., Genoulaz, O., Gratacap-Cavallier, Detection in Water and Food. Food Anal.
B. Chevallier, P., Liu, J.-X. & Seigneurin, J.-M. Methods 4, 4–12 (2011).
Ultrafiltration and reverse transcription-poly- 21. Masciopinto, C. et al. Unsafe tap water in
merase chain reaction: an efficient process households supplied from groundwater in
for poliovirus, rotavirus and hepatitis A virus the Salento Region of Southern Italy. J.
detection in water. Water Res. 34, 1063–1067 Water Health 5, 129–148 (2007).
(2000). 22. Dreier, J., Störmer, M., Mäde, D., Burkhardt,
6. Bergh, O., BOrsheim, K. Y., Bratbak, G. & S. & Kleesiek, K. Enhanced reverse
Heldal, M. High abundance of viruses found transcription-PCR assay for detection of
in aquatic environments. Nature 340, norovirus genogroup I. J. Clin. Microbiol. 44,
467–468 (1989). 2714–2720 (2006).
7. Hulo, C. et al. ViralZone: A knowledge resource 23. Maunula, L. et al. Enteric Viruses in a Large
to understand virus diversity. Nucleic Acids Waterborne Outbreak of Acute Gastro-
Res. 39, 576– 582 (2011). enteritis in Finland. Food Environ. Virol. 1,
8. Hagen, S. et al. Modular adeno-associated 31–36 (2009).
virus (rAAV) vectors used for cellular virus- 24. Wommack, K. E. & Colwell, R. R. Virioplankton:
directed enzyme prodrug therapy. Sci. Rep. 4, viruses in aquatic ecosystems. Microbiol.
3759 (2014). Mol. Biol. Rev. 64, 69–114 (2000).
9. Schindler, S. E. et al. Photo-activatable Cre 25. Parada, V., Baudoux, A.-C., Sintes, E.,
recombinase regulates gene expression in Weinbauer, M. G. & Herndl, G. J. Dynamics
vivo. Sci. Rep. 5, 13627 (2015). and diversity of newly produced virioplank-
10. Scherr, M. et al. Efficient gene transfer into ton in the North Sea. ISME J. 2, 924–936
the CNS by lentiviral vectors purified by (2008).
anion exchange chromatography. Gene 26. Schroeder, D. C., Oke, J., Hall, M., Malin,
Ther. 9, 1708–1714 (2002). G. & Wilson, W. H. Virus Succession
11. Granato, M. et al. HCV derived from sera of Observed during an Emiliania huxleyi
HCV- infected patients induces pro-fibrotic Bloom Virus. Appl. Environ. Microbiol. 69,
effects in human primary fibroblasts by acti- 2484– 2490 (2003).
vating GLI2. Sci. Rep. 6, 30649 (2016). 27. Allen, M. J. et al. Locus-Specific Gene
12. Martin, L. et al. Rational design of a CD4 Expression Pattern Suggests a Unique
mimic that inhibits HIV-1 entry and exposes Propagation Strategy for a Giant Algal Virus.
cryptic neutralization epitopes. Nat. J. Virol. 80, 7699–7705 (2006).
Biotechnol. 21, 71–76 (2003). 28. Brussaard, C. P. D., Noordeloos, A. A. M.,
13. Karlas, A. et al. A human genome-wide loss- Sandaa, R. A., Heldal, M. & Bratbak, G.
of-function screen identifies effective chi- Discovery of a dsRNA virus infecting the
kungunya antiviral drugs. Nat. Commun. 7, marine photosynthetic protist Micromonas
11320 (2016). pusilla. Virology 319, 280–291 (2004).
14. Nestola, P. et al. Rational development of 29. Fischer, M. G. & Hackl, T. Host genome
two flowthrough purification strategies for integration and giant virus-induced
adenovirus type 5 and retro virus-like reactivation of the virophage mavirus.
particles. J. Chromatogr. A 1426, 91–101 Nature 540, 288–291 (2016).
(2015). 30. Liu, H. et al. Cross-Neutralization of a SARS-
15. Carvalho, L. S. et al. Long-term and age- CoV-2 Antibody to a Functionally Con-
dependent restoration of visual function in served Site Is Mediated by Avidity. Immunity
a mouse model of CNGB3-associated 53, 1272-1280 (2020)
achromatopsia following gene therapy.
Hum. Mol. Genet. 20, 3161–3175 (2011).

31. Tan, T.K. et al. A COVID-19 vaccine 41. Gierer, S. et al. The spike protein of the
candidate using SpyCatcher multimeriza- emerging betacoronavirus EMC uses a
tion of the SARS-CoV-2 spike protein novel coronavirus receptor for entry, can be
receptor-binding domain induces potent activated by TMPRSS2, and is targeted by
neutralizing antibody responses. Nature neutralising antibodies. J. Virology 87,
Communications 12:542 (2021) 5502-5511 (2013).
32. Kuate, S. et al. Exosomal vaccines contain- 42. Masters, P. S. The Molecular Biology of
ing the S protein of the SARS coronavirus Coronaviruses. Adv. Virus Research 66,
induce high levels of neutralizing antibod- 193-292 (2006)
ies. Virology 362, 26-37 (2007). 43. Larsen, D. A, Wigginton K R. Tracking
33. Würdinger, T. et al. Soluble receptor- COVID-19 with Wastewater. Nature
mediated targeting of mouse hepatitis Biotechnology 38, 1151-1153 (2020).
coronavirus to the human epidermal growth 44. Trottier, J. et al. Post-lockdown detection of
factor receptor. J. Virology 79, 15314-15322 SARS-CoV-2 RNA in the in the wastewater
(2005) of Montpellier, France. One Health 10
34. Jansson, A. M. Structure of Alphacoronavirus (2020)
transmissible gastroenteritis virus nsp1 has 45. Hokkaido University. SARS-CoV-2 RNA
implications for coronavirus nsp1 function Detected in Untreated Wastewater from
and evolution. J Virology 87, 2949-2955 Louisiana. ScienceDaily. (26 Aug 2020)
(2013), 46. Jafferalli, M. H. et al. Benchmarking virus
35. Justyna, A. et al. Structure of the X (ADRP) concentration methods for quantification of
domain of nsp3 from feline coronavirus. Bio. SARS-CoV-2 in raw wastewater. Science of
Crystallography 65, 1292-1300 (2009). the Total Environment 10, 755, (2021)
36. Bertram, S, et al. Cleavage and activation of 47. Dumke, R. et al. Evaluation of Two Methods
the severe acute respiratory syndrome to Concentrate SARS-CoV-2 from Untreat-
coronavirus spike protein by human airway ed Wastewater. Pathogens 195 (2021)
trypsin-like protease. J Virology 85, 13363- 48. Takayuki, M. et al. Virus type-specific remov-
13372 (2011). al in a full-scale membrane bioreactor treat-
37. Walls, A. C. et al. Glycan shield and epitope ment process. Food and Env. Virology 10,
masking of a coronavirus spike protein 176-186 (2017).
observed by cryo-electron microscopy. 49. Sima, L. C. et al. Calicivirus removal in a
Nature Str & M. Biology 23 (2016). membrane bioreactor wastewater treat-
38. Schroeder, S. et al. Functional comparison ment plant. Applied and Inv. Microbiology
of MERES-coronavirus lineages reveals 77, 5170-5177 (2011).
increased zoonotic potential of the recom- 50. Schaeffer, J. et al. Improving the efficacy
binant lineage 5. Pending publication. of sewage treatment decreases norovirus
39. Signer, J. In vitro antiviral activity of contamination in oysters. Int. J. of Food
Echinaforce®, an Echinacea purpurea Microbiology 286, 1-5 (2018).
preparation, against common cold corona- 51. Takayuki, M. et al. Detection of hepatitis E
virus 229E and highly pathogenic MERS- virus in sewage after an outbreak on a
CoV and SARS-CoV. Pending publication French island. Food and Env. Virology 8,
40. Pastorino, B. et al. Evaluation of heating and 194-100 (2016).
chemical protocols for inactivating SARS-
CoV-2. Pending publication

5. Sartorius Ultrafiltration Products in the Preparation
of Biological Nanoparticles and Medical Nanocarriers
Introduction olecular weight cut-off, MWCO).
m
Paul Ehrlich was inspired by the idea The Vivaspin® portfolio spans a volume
of the “magic bullet”* when he for the range from 0.1 to 20 mL, whereas the
first time described in theory toxic Vivaflow® system covers volumes from
drugs assembled to so-called “Nano- 0.1 to 5 liters. Thus, Sartorius offers an
carriers” in 1908.¹ Today, Nanocarriers unrivaled wide range of processable
have found multiple applications in sample volumes, membrane materials
modern medicine and biotechnology. and MWCOs to meet the different
A key application for these special requirements of their intended use.
nanomaterials is a targeted delivery Challenges in this context are buffer
of drugs where they act as transport exchange after synthesis, desalting
modules (i. e. as nanoparticles, vesicles, and washing,¹⁰,¹¹ exclusion of solubi-
or micelles) for the active ingredi- lized compounds,¹²,¹³,¹⁴ or aggregates.¹⁵
ent.²,³,⁴,⁵ This is assumed to be more
effective and less toxic to the (human) Purification is essential to obtain
organism compared to traditionally isosmotic conditions for in vivo
administered drug substances.⁶ applications, to prevent aggregation
Besides drug delivery, various further or agglomeration and to remove free
fields using Nanocarriers evolved toxic drugs, ligands, or other sub-
during the last decades; e. g. magnetic strates potentially triggering side
resonance imaging or stem cell gene effects. Concentration steps are
therapy with metal-based nano essential to adjust the amount of
particles,⁷,⁸ or optical imaging with pharmaceutical active ingredient in
quantum dots.⁹ the drug and achieve the anticipated
therapeutic or diagnostic effect.
Nanocarriers can be categorized by
their starting material (i. e. metal-, During purification, the separation of
lipid-, polymer-, and protein-based) free substances (starting material)
and by their formation after prepara- from the desired Nanocarriers via size-
tion (i. e. vesicles, particles and mi- exclusion chromatography (SEC) leads
celles). In general, the preparation of to an unavoidable dilution and to the
a nanoparticle suspension or a vesicle necessity of a subsequent concentra-
dispersion in an aqueous medium tion step. In contrast, dialysis purifies
consists of three steps: a) assembly without significant dilution but a con-
of the Nanocarriers (for example, by centration step can still be mandatory,
injections, film hydration, or reverse if higher Nanocarrier concentrations
phase evaporation), b) purification are necessary. Both separation meth-
(for example, by chromatography, ods require quite extensive, costly and
dialysis or ultrafiltration), and c) timeconsuming manual handling.
concentration (for example, by This drawback is overcome with the
ultrafiltration or evaporation). ultrafiltration utilized by centrifugation
in Vivaspin® or with a peristaltic pump
This short review provides examples for the Vivaflow® system. This tech-
of recent literature dealing with the nique is less expensive and quickly
preparation of Nanocarriers. Particular performed with very little manual
focus is laid on the concentration and input. Noteworthy is that purification
purification steps which were per- and concentration steps are performed
formed via ultrafiltration with Sartorius simultaneously.¹⁶
Vivaspin® or Vivaflow® devices with
different pore sizes (respectively
* In German “Zauberkugel”, opera “Freischütz”
by Carl Maria von Weber
Application Note 5. Ultrafiltration of Nanoparticles 95

After the Nanocarrier is purified, Prior to performing these different
the determination of drug loading characterizations, a successful
(conjugation or encapsulation purification and concentration of the
efficiency) is commonly performed. suspension or dispersion is essential.
The conjugation or encapsulation
efficiency is one of the reference In the following tables you can find
values to describe and characterize an overview of publications using
Nanocarriers. Other important proper- ultrafiltration steps for the purification
ties are the zeta potential and the size and concentration of different kinds
distribution determined via photon of Nanocarriers. Table 2 provides
correlation spectroscopy (PCS), guidance on which devices and
high-resolution transmission electron MWCOs to use.
microscopy (HRTEM) imaging, or
dynamic light scattering (DLS).
Table 1 summarizes examples of Nanocarrier ultrafiltration applications with Sartorius Vivaspin® or Vivaflow®:
Nanocarrier: Size distribution obtained via (HR)TEM or DLS, Application Ref.

Nanoparticle, Vesicle, Micelle Z-Average via PCS and others-if reported
Nanoparticles from metal, metal oxides and functionalized metals
Iron oxides nanoparticles with SD: 4.5 ± 0.9 nm via X-Ray-Diffraction Analysis Magnetic resonance imaging 7
cisplatinbearing polymer coating
Functionalized iron oxide nanoparticles SD: 38 and 40 nm via DLS Stem cell gene therapy and tracking 8
Gold nanoparticles SD: 0.8 – 10.4 nm via Atomic Force Microscopy Antimicrobial activity 17
Protein coated gold nanoparticles SD: 15 and 80 nm via TEM Drug delivery 18
Functionalized gold nanoparticles Core-SD: 2 nm via TEM Targeted imaging tool and antigen delivery 19
Functionalized gadolinium-based Z-Average: 1.1 ± 0.6 nm and 4 – 14 nm Diagnostic and therapeutic application 20, 21
nanoparticles
Functionalized nanocrystals 10 to 20 nm Quantum dots for imaging 9
Nanoparticles from polymers, functionalized polymers and polymersomes
Polymer based Nanoparticles Drug delivery 22
Curdlan coated polymer nanoparticles Z-Average: 280 – 480 nm depending on the Macrophage stimulant activity 23
composition and drug delivery
Docetaxel-carboxymethylcellulose Z-Average: 118 ± 1.8 nm Anti-cancer efficacy studies 4

Polymer Nanoparticles
Functionalized Polymersomes Z-Average: 185 nm Surface functionalization studies 3
96 Application Note 5. Ultrafiltration of Nanoparticles

Lipid Nanoparticles and Liposomes
Liposomes and micelles Z-Average: 100 nm for Liposomes and 15 nm Ischemia-reperfusion injury 25
for micelles
Solid lipid Nanoparticles Z-Average: 100 – 120 nm depending on the Drug delivery (Brain Targeting) 26
used lipid
Bacterial outer membrane vesicles SD: 124 nm via TRPS Tunable resistive pulse sensing (TRPS) 27
Analysis
Bacterial outer membrane vesicles Basic research 28
Bacterial outer membrane vesicles SD: 95 nm Basic research 29
Bacterial outer membrane vesicles SD: 50 – 150 nm via TEM Basic research 30
Liposomes Drug delivery 2
Liposomes Encapsulated hydrophilic drugs (Drug delivery) 31
Micelles
Micelles Drug delivery 4
Hydrophobic drug micelles SD via DLS: 39 – 165 nm depending on Drug delivery 14

based on polymers compound in use
Protein Nanoparticles
Protein Nanoparticles SD: 20 – 40 nm via DLS Drug carrier studies 32
SD = Size distribution

Table 2 lists example Sartorius devices and typical MWCOs used for each nanocarrier ultrafiltration application:
Nanocarrier: Sartorius MWCO Ultrafiltration purpose Ref.

Nanoparticle, Vesicle, Micelle Ultrafiltration Device
Nanoparticles from metal, metal oxides and functionalized metals
Iron oxides nanoparticles with Vivaspin® 20 100 kDa Purification and concentration 7
cisplatinbearing polymer coating
Functionalized iron oxide nanoparticles Vivaspin® 20 100 kDa Washing step 8
Gold nanoparticles Vivaspin 20

®
5 kDa Purification step 17
Protein coated gold nanoparticles Vivaspin® 6 10 kDa Separation of Nanoparticles | Dyes and washing 18
Functionalized gold nanoparticles Vivaspin® 10 kDa Purification step 19
Functionalized gadolinium-based Vivaspin® 5 kDa Purification and concentration 20, 21

nanoparticles and 10 kDa
Functionalized nanocrystals Vivaspin® 300 kDa Separation of quantum dots-antibody conjugates 9

and 50 kDa from starting material (prior to enumeration)
Nanoparticles from polymers, functionalized polymers and polymersomes
Polymer based Nanoparticles Vivaspin® 30 kDa Purification and concentration 22
Curdlan coated polymer nanoparticles Vivaspin 20®

3 kDa Washing 23
Docetaxel-carboxymethylcellulose Vivaspin ®
10 kDa Concentration 4
Polymer Nanoparticles
Functionalized Polymersomes Vivaspin® 20 10 kDa Concentration 3
Lipid Nanoparticles and Liposomes
Liposomes and micelles Vivaspin® 20 100 kDa Concentration 25
Solid lipid Nanoparticles Vivaflow® 50 100 kDa Purification 26
Bacterial outer membrane vesicles Vivaflow® 200 100 kDa Buffer exchange and concentration 27
Bacterial outer membrane vesicles Vivaspin® 500 and 20 100 kDa Buffer exchange and concentration 28
Bacterial outer membrane vesicles Vivaflow 200

®
100 kDa Buffer exchange and concentration 29
Bacterial outer membrane vesicles Vivaspin ®

100 kDa Buffer exchange and concentration 30
Liposomes Vivaspin ®
100 kDa External buffer exchange 2
Liposomes Vivaflow 50®

100 kDa Elimination of the free drug 31
Micelles
Micelles Vivaspin® 30 kDa Separation of free substrate and concentration 4
Hydrophobic drug micelles Vivaflow ®

Surfactant removal 14
based on polymers
Protein Nanoparticles
Protein Nanoparticles Vivaspin® 500 3 kDa Separation of the free from the encapsulated drug 32
(Drug binding quantification by subsequent
UV-vis analysis)

References 14 Zhang, Y. et al.: Therapeutic surfactant-
1. Strebhardt, K. & Ullrich, A.: Paul Ehrlich’s stripped frozen micelles. Nat Commun 7,
magic bullet concept: 100 years of progress. 11649 (2016).
8, 473–480 (2008). 15 Klasson, A. et al.: Positive MRI contrast
2 Jakoby, J., Beuschlein, F., Mentz, S., Hantel, enhancement in THP-1 cells with Gd2O3
C. & Süss, R.: Liposomal doxorubicin for active nanoparticles. Contrast Media Mol.
targeting: Surface modification of the Imaging 3, 106–111 (2008).
nanocarrier evaluated in vitro and in vivo – 16 Simonoska Crcarevska, M. et al.: Definition of
challenges and prospects. Oncotarget 6, formulation design space, in vitro bioactivity
(2015). and in vivo biodistribution for hydrophilic
3 Klermund, L., Poschenrieder, S. T. & Castiglione, drug loaded PLGA/PEO-PPO-PEO
K.: Simple surface functionalization of nanoparticles using OFAT experiments. Eur.
polymersomes using non-antibacterial J. Pharm. Sci. 49, 65–80 (2013).
peptide anchors. J. Nanobiotechnology 14, 17 Boda, S. K. et al.: Cytotoxicity of Ultrasmall
48 (2016). Gold Nanoparticles on Planktonic and
4 Mulder, W. J. M. et al.: Molecular imaging of Biofilm Encapsulated Gram-Positive
macrophages in atherosclerotic plaques Staphylococci. Small 11, 3183–3193 (2015).
using bimodal PEG-micelles. Magn. Reson. 18 Schäffler, M. et al.: Blood protein coating of
Med. 58, 1164–1170 (2007). gold nanoparticles as potential tool for organ
5 Murthy, S. K.: Nanoparticles in modern medi- targeting. Biomaterials 35, 3455–3466
cine: state of the art and future challenges. (2014).
Int. J. Nanomedicine 2, 129–41 (2007). 19 Arosio, D. et al.: Effective targeting of
6 Voigt, R. & Fahr, A.: Pharmazeutische DC-sign by α-fucosylamide functionalized
Technologie für Studium und Beruf. gold nanoparticles. Bioconjug. Chem. 25,
Deutscher Apotheker Verlag, 10th Edition 2244–2251 (2014).
(2010). 20 Miladi, I. et al.: Biodistribution of ultra small
7 Unterweger, H. et al.: Development and gadolinium-based nanoparticles as
characterization of magnetic iron oxide theranostic agent: application to brain
nanoparticles with a cisplatin-bearing tumors. J. Biomater. Appl. 28, 385–94
polymer coating for targeted drug delivery. (2013).
Int J Nanomedicine 9, 3659–3676 (2014). 21 Faure, A. C. et al.: Control of the in vivo
8 Park, W. et al.: Multi-modal transfection biodistribution of hybrid nanoparticles with
agent based on monodisperse magnetic different poly(ethylene glycol) coatings.
nanoparticles for stem cell gene delivery Small 5, 2565–2575 (2009).
and tracking. Biomaterials 35, 7239–7247 22 Benita, S., Debotton, N. & Goldstein, D.:
(2014). Nanoparticles for Targeted Delivery of
9 Chalmers, N. I. et al.: Use of quantum dot Active Agent. (2008).
luminescent probes to achieve single-cell 23 Tukulula, M. et al.: Curdlan-conjugated
resolution of human oral bacteria in biofilms. PLGA nanoparticles possess macrophage
Appl. Environ. Microbiol. 73, 630–636 (2007). stimulant activity and drug delivery
10 Hoffman, L. W., Andersson, G. G., Sharma, A., capabilities. Pharm. Res. 32, 2713–2726
Clarke, S. R. & Voelcker, N. H.: New insights (2015).
into the structure of PAMAM dendrimer | 24 Ernsting, M. J., Tang, W. L., MacCallum, N.
gold nanoparticle nanocomposites. W. & Li, S. D.: Preclinical pharmacokinetic,
Langmuir 27, 6759–6767 (2011). biodistribution, and anti-cancer efficacy
11 Rademacher, T. & Williams, P.: Nanoparticle- studies of a docetaxel-carboxymethyl
peptide compositions. (2014). cellulose nanoparticle in mouse models.
12 Allard, E. & Larpent, C.: Core-shell type Biomaterials 33, 1445–1454 (2012).
dually fluorescent polymer nanoparticles for 25 Geelen, T., Paulis, L. E., Coolen, B. F.,
ratiometric pH-sensing. J. Polym. Sci. Part A Nicolay, K. & Strijkers, G. J.: Passive target-
Polym. Chem. 46, 6206–6213 (2008). ing of lipid-based nanoparticles to mouse
13 Prach, M., Stone, V. & Proudfoot, L.: Zinc cardiac ischemia-reperfusion injury.
oxide nanoparticles and monocytes: Impact Contrast Media Mol. Imaging 8, 117–126
of size, charge and solubility on activation (2013).
status. Toxicol. Appl. Pharmacol. 266, 19–26
(2013).

26 Neves, A. R., Queiroz, J. F. & Reis, S.:
Brain-targeted delivery of resveratrol using
solid lipid nanoparticles functionalized with
apolipoprotein E. J. Nanobiotechnology 14,
27 (2016).
27 Bogomolny, E. et al.: Analysis of bacteria-
derived outer membrane vesicles using
tunable resistive pulse sensing. Prog.
Biomed. Opt. Imaging – Proc. SPIE 9338,
4–9 (2015).
28 Blenkiron, C. et al.: Uropathogenic
Escherichia coli releases extracellular
vesicles that are associated with RNA.
PLoS One 11, 1–16 (2016).
29 Twu, O. et al.: Trichomonas vaginalis
Exosomes Deliver Cargo to Host Cells and
Mediate Host:Parasite Interactions. PLoS
Pathog. 9, 22–24 (2013).
30 Tong, T. T., Mörgelin, M., Forsgren, A. &
Riesbeck, K.: Haemophilus influenzae
Survival during Complement-Mediated
Attacks Is Promoted by Moraxella
catarrhalis Outer Membrane Vesicles.
J. Infect. Dis. 195, 1661–1670 (2007).
31 Prado, J. M. D., Antoranz, J. R. C., Barroeta,
M. Á. E., Barroeta, B. E. & Diaz, M. C.:
Liposomal formulations. (2009).
32 Achilli, E. et al.: Preparation of protein
nanoparticle by dynamic aggregation and
ionizing-induced crosslinking. Colloids
Surfaces A Physicochem. Eng. Asp. 486,
161–171 (2015).

6. Vivaflow® and Vivaspin® Workflow in Protein
Research Laboratories
Introduction Methods
Efficiency and efficacy of a multiple
cycle experimental procedure was Part 1 – Creating and concentrating
performed using Vivaflow® tangential the culture medium
flow cassettes for initial concentration 2 bottles (4 g) of RPMI-1640 were
and diafiltration of a cell culture super- dissolved into 1.8 L dd-H2O and 4 g
natant. This was followed by Vivapure® of sodium acetate was added.
Ion Exchange spin columns for the
protein purification step and finally The pH was adjusted to 7.2 using 1M
Vivaspin® 20 ultrafiltration devices for HCl. 2 g of BSA and 1 g of Lysozyme
the final sample concentration and was added as protein samples, meant
desalting. An artificial mixture of to be separated by chromatography.
proteins in a RPMI-1640 culture The volume of the cell culture super-
medium was created to mimic the natant sample was brought up to 2 L
type of product that many researchers using dd-H₂O. After every preparation,
culture using e.g. the UniVessel device. concentration and purification step, 1
This procedure further reflects a mL sample was set aside for SDS gel
*S
ample colour
representative only
method that can be adapted to a analysis.
large number of protein purification
protocols, selecting alternative Ion exchange chromatography was
MWCOs and device sizes where the method of choice for purifying
necessary. lysozyme from the cell culture
supernatant, especially from the
“contaminant” BSA. For this, the 2 L
cell culture supernatant needed to be
concentrated and then diafiltered to
adjust the sample to the starting
conditions needed for the ion exchange
chromatography binding step.
For concentration and diafiltration, the

Vivaflow® 200 was used with a 5 kDa
MWCO PES membrane. Vivaflow®
200 is a ready-to-use laboratory cross-
flow cassette in an acrylic housing,
which allows caustic cleaning and 4 – 5
re-uses. Two cassettes can be run in
parallel for the concentration of up to
5 L sample volumes. For the 2 L sample
to be concentrated in this experiment,
one cassette was sufficient. A M
asterflex
pump with an Easy-Load, size 16 pump
head was used to run the Vivaflow® 200
cassette. Figure 1a. and 1b. show the
Vivaflow® 200 set up with one or two
cassettes.
Application Note 6. Vivaflow® and Vivaspin® Workflow 101

The Vivaflow® 200 system was operated Filtrate Volume (mL) Time (hr:min:sec)
at 3 bar. Once 1.8 L of filtrate had been 0 0:00:00
collected, the pump was stopped, the
100 0:03:16
tubes removed from the cell culture
medium concentrate and filtrate and 200 0:06:50
the Vivaflow® system was purged with 300 0:10:45

dd-H₂O. This solution now contained a 400 0:14:38
10-fold concentration of the constitu-
500 0:18:36
ent proteins from the original culture
600 0:22:43
medium.
700 0:26:57
A BCA protein detection assay con- 800 0:31:14
veyed a 100% recovery of protein after 900 0:36:01
this first concentration step. Table 1
1,000 0:40:50
indicates the time needed for the
sample concentration. 1,100 0:45:46
1,200 0:50:36
1,300 0:55:32
1,400 1:00:24
1,500 1:05:26
1,600 1:10:28
1,700 1:15:52
1,800 1:21:50
Table 1: Vivaflow® 200, 5 kDa MWCO PES

concentration speed
Figure 1a. Vivaflow® 200 – single cassette
Figure 1b. Vivaflow® 50R – two cassettes
102 Application Note 6. Vivaflow® and Vivaspin® Workflow

Part 2 – Buffer exchange of culture
medium concentrate
The Vivaflow® 200 system was used for
fast and easy diafiltration. To this end,
the diafiltration reservoir, a Vivaflow®
accessory, was filled with the 200 mL
concentrated sample. Figure 2 shows
the diafiltration set up. The Vivaflow®
200 system was set up as before,
however attaching an additional tube Figure 2: Diafiltration system set up for buffer
to the diafiltration lid and placing this exchange. Culture medium concentrate can
be seen in the center of the image. 1 L 25 mM
new inlet tube into a 25 mM sodium
sodium acetate (exchange buffer) can be seen
acetate (pH 5.5) buffer (needed to connected to the system on the left of the
re-adjust the sample concentrate to image.
the ionic starting conditions of the ion
exchange chromatography step which
was to follow). This enables concentra- Filtrate Volume (mL) Time (hr:min:sec)
tion of the sample in the reservoir to 0 0:00:00
the extent that the original buffer is
100 0:06:58
removed and collected as waste
(filtrate). Simultaneously, new buffer 200 0:14:16
(25 mM sodium acetate) is drawn into 300 0:22:39
the closed system, gradually leading to 400 0:29:40
a buffer exchange while keeping the
500 0:37:02
sample volume constant at 200 mL.
600 0:44:15
The system was run at 3 bar. Once 1 L
of buffer had been exchanged, 700 0:51:34
diafiltration was stopped. 800 0:58:54
900 1:06:03
The 200 mL solution now contained
1,000 1:13:02
the correct buffer to maintain the
stability of the proteins of interest for Table 2: Diafiltration of 200 mL concentrated
the next part of the protocol and had cell culture supernatant containing the proteins
lysozyme and BSA against 1,000 mL 25 mM
the correct pH and salt concentration
sodium acetate.
for the ion exchange binding step.
BCA protein quantification again
showed a 100% protein recovery.
Table 2 shows the time needed for

diafiltration of 200 mL sample against
1,000 mL exchange buffer, again using
Vivaflow® 200 with a 5 kDa MWCO
PES membrane.

Part 3 – Purification of Lysozyme, Two Vivapure® Maxi H S type devices
the protein of interest (Figure 4) were each equilibrated
The purification of Lysozyme was with 10 mL of 25 mM sodium acetate
performed using a Vivapure® cation (pH 5.5), by filling with 10 mL of this
exchange membrane adsorber device buffer and centrifuging for 5 min. in a
(Vivapure® Maxi H S). The membrane swing bucket centrifuge at 500 g and
adsorber matrix holds the active discarding the flow through. Using the
ligands and performs like a traditional concentrated and buffer exchanged
cation exchanger. However, mem- sample from Part 2, 10 mL samples
brane adsorbers represent a special were pipetted into each of the
form of chromatography matrix. equilibrated Vivapure® devices and
Unlike traditional resins, they make centrifuged again for 5 min. in a
use of convective transport to bring swing bucket centrifuge at 500 g.
proteins to the ion exchange surface; The Vivapure® devices were washed
hence, binding, washing and elution with 10 mL of 25 mM sodium acetate,
is performed quickly and high binding discarding the flow through, followed
capacities are achieved, even at high by an elution step with 5 mL of 1 M
flow rates. This allows their use in fast NaCl in 25 mM sodium acetate. A BCA
and convenient centrifugal spin assay revealed 95% lysozyme recovery.
columns (Figure 3).
Figure 3: Electron micrograph of chromatogra- Figure 4: Vivapure® Maxi spin columns can be
phy gel beads (upper right) in comparison to a used in a centrifuge for fast and easy protein
Q ion exchange membrane adsorber (back- purification.
ground), revealing 100-fold larger pore sizes of
the membrane adsorber.

The eluate was then concentrated in Part 4 – Analyzing the samples
a Vivaspin® 20 (5 kDa MWCO PES), The samples of the individual steps
Figure 5, and centrifuged at 5,000 g were analyzed by SDS gel, using
for 10 min. or until approximately 2 mL reducing sample buffer (prepared by
of concentrate had been collected. adding 50 μL 2-mercaptoethanol to
The device was then re-filled with 950 μL Laemmli sample buffer). For all
18 mL 50 mM potassium phosphate steps, 5 μL of the 1 mL sample taken
buffer (pH 7.2) to 20 mL for a final during the experiment were diluted
buffer exchange and desalting of the with 95 μL reducing sample buffer, of
purified sample. The sample was again which 20 μL were loaded onto a 12%
centrifuged until a final sample volume Tris-HCl SDS gel (Figure 6).
of 2 mL had been attained. A BCA
assay revealed 97% lysozyme recovery.
Figure 6: Coomassie stained 12% Tris-HCl SDS

gel loaded with 20 μL sample preparations.
Lane 1: Marker (SDS Broad Range); Lane 2:
Original sample; Lane 3: Original sample filtrate
(Part 1); Lane 4: Marker; Lane 5: Buffer exchange
concentrate (Part 2); Lane 6: Filtrate after
Figure 5: Vivaspin® 20 ultrafiltration device, on binding (Part 3); Lane 7: Marker; Lane 8: Filtrate
the right with a pressure cap which allows pres- after elution (Part 3); Lane 9: Filtrate after
surization of the device as an alternative to the concentrating and desalting (Part 3); Lane 10:
regular centrifugal operation. Concentrate after concentrating and desalting.

Conclusion Task Time Recovery
The overall result shows that a stan- Vivaflow® 200 1 hour 25 min. 100%
dard and straightforward procedure set up and
concentration
can be followed to concentrate, purify,
isolate and analyze a protein of interest Vivaflow® 200 1 hour 20 min. 100%
set up and
from a cell culture, using Vivaflow®
diafiltration
200 tangential flow units for cell
culture supernatant concentration Vivapure® 45 min. 95%
purification
and diafiltration, Vivapure® for ion
exchange chromatography, followed Vivaspin® 30 min. 97%
concentration
by Vivaspin® 20 for final sample and desalting
concentration and desalting.
Total 3 hours 45 min. 92%
In many cases dialysis, which is an

overnight procedure would be per- Products used in this Order No.
formed instead of the much quicker experiment
alternative - ultrafiltration. Here, we Vivaflow® 200, VF20P1
show how time-saving and efficient 5 kDa MWCO PES
ultrafiltration is for diafiltration and 500 mL Diafiltration Reservoir VFA006
desalting applications, as well as for Vivapure® S H Maxi VS-IX20SH08
protein concentration.
Vivaspin 20,
®
VS2011
5 kDa MWCO PES
The set up and completion of protein
purification takes approx. 3.45 h using Table 3: Processing times for a complete
this method, starting from a culture protein purification workflow.
supernatant, with high protein recov-
eries in each step (see Table 3). A total
protein purification procedure can
therefore be completed within 1 working
day, including SDS gel analysis, utilizing
this strategy, when adapted to
individual needs.

Germany USA
Sartorius Lab Instruments GmbH & Co. KG Sartorius Corporation
Otto-Brenner-Straße 20 565 Johnson Avenue
37079 Göttingen Bohemia, NY 11716
Phone +49 551 308 0 Phone +1 631 254 4249
Toll-free +1 800 635 2906
F
or further information, visit
www.sartorius.com
Specifications subject to change without notice.

Copyright Sartorius Lab Instruments GmbH & Co. KG.
Status: 05| 2022

Lab Ultrafiltration and Purification Products Catalog

Uploaded by

Copyright:

Available Formats

Lab Ultrafiltration and Purification Products Catalog

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Lab Ultrafiltration and Purification Products Catalog

Uploaded by

Copyright:

Available Formats

Lab Ultrafiltration

Tangential Flow Filtration

Ultrafiltration Membrane Discs 42

Virus Purification and Concentration 59

Ultrafiltration is a convective process Solute Concentration

recovery, reliability and robustness. Visit www.sartorius.com for more

technical and application support

Ultrafiltration Process Methods

Sartorius offers a comprehensive Pressure-Fugation

Centrifugal Crossflow | TFF

Sartorius offers an extended range of This is a hydrophillic membrane

Membrane Performance Comparisons

Membrane Frequently preferred for:

Polyethersulfone & Regenerated Cellulose Concentration

Cellulose triacetate Deproteinization

Membrane Selection Guide (Recommended MWCO)

Vivaspin® Turbo 4 PES 16

Vivaspin® Turbo 15 PES 24

Vivaspin® Equipment and Accessories 32

Vivaflow® Equipment and Accessories 40

Ultrafiltration Membrane Discs 42

100 to 500 μL samples The legacy patented vertical

Swing bucket rotor do not use

Fixed angle rotor 500 µL

Active membrane area 0.5 cm²

Hold-up volume, membrane and support < 5 µL

11 Body Polycarbonate (PC)

Filtrate vessel Polypropylene (PP)

Concentrator cap Polycarbonate (PC)

Membrane Polyethersulfone (PES)

Rotor type Fixed angle (min. 40°)

Rotor cavity To fit 2.2 mL (11 mm) conical bottom tubes

Maximum RCF 12,000 g

Pipette type Fixed or variable volume

Recommended tip Thin gel loader type

10 Protein Concentration Centrifugal Filtration Vivaspin® 500

Time to concentrate up to 30x

Rotor Fixed angle

Centrifugal force 12,000 g

Start volume 500 µL

Aprotinin 0.25 mg/mL (6.5 kDa)

BSA 1.0 mg/mL (66 kDa)

IgG 0.25 mg/mL (160 kDa)

Vivaspin® 500 PES 25 pc 100 pc

3 kDa MWCO VS0191 VS0192

5 kDa MWCO VS0111 VS0112

10 kDa MWCO VS0101 VS0102

30 kDa MWCO VS0121 VS0122

50 kDa MWCO VS0131 VS0132

100 kDa MWCO VS0141 VS0142

300 kDa MWCO VS0151 VS0152

1,000 kDa MWCO VS0161 VS0162

0.2 µm VS0171 VS0172

Protein Concentration Centrifugal Filtration Vivaspin® 500 11

0.4 to 3 mL samples Also unique to Vivaspin® 2 is the

Available with a choice of

20 Swing bucket rotor 3 mL

Fixed angle rotor 2 mL

Length x diameter 126 x 17 mm